<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ebm.bmj.com">
<title>Evidence-Based Medicine Online First</title>
<link>http://ebm.bmj.com</link>
<description>Evidence-Based Medicine RSS Feed -- Online First</description>
<prism:publicationName>Evidence-Based Medicine</prism:publicationName>
<prism:issn>1356-5524</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100709v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100388v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100557v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100673v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100570v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100538v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100574v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100562v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100677v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100631v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100634v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100287v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100515v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100509v2?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100433v2?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100549v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100672v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100564v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100571v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100632v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100584v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100424v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100440v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100555v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100452v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100450v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100493v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100265v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100415v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100525v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100451v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100481v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100522v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100454v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100343v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100383v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100412v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100065v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100489v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100337v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100227v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100358v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100479v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100472v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100471v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100422v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100477v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100478v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100469v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100473v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100381v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100334v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100361v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100332v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100355v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100345v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100353v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100318v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100378v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100147v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100230v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100278v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100206v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100310v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100167v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100215v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100183v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100193v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100212v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100221v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100162v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100238v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100202v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100252v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100231v1?rss=1" />
  <rdf:li rdf:resource="http://ebm.bmj.com/cgi/content/short/ebm.2011.100121v1?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.ebm.bmj.com/homepage/EBM_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.ebm.bmj.com/homepage/EBM_95x60.gif">
<title>Evidence-Based Medicine</title>
<url>http://hwmaint.ebm.bmj.com/homepage/EBM_95x60.gif</url>
<link>http://ebm.bmj.com</link>
</image>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100709v1?rss=1">
<title><![CDATA[Topical dexamethasone for recurrent aphthous ulceration reduces pain and size and increases healing with no significant adverse events]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100709v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Recurrent aphthous ulceration or stomatitis (RAS) is a common condition characterised by painful recurring oral ulcers, typically commencing in childhood. These ulcers classically present as round or oval lesions, and have a yellow or grey base and a surrounding erythematous inflammatory halo. Although &lsquo;aphthous-like ulcers&rsquo; can be associated with a number of systemic diseases, &lsquo;recurrent aphthous ulceration&rsquo; is a term that should strictly be reserved for recurring ulcers arising in the absence of associated systemic disease.<cross-ref type="bib" refid="R1">1</cross-ref> The lifetime prevalence of RAS has been estimated at 36.5%<cross-ref type="bib" refid="R2">2</cross-ref> and approximately 80% of all are recurring minor type aphthae,<cross-ref type="bib" refid="R1">1</cross-ref> rather than major or herpetiform type, the other described aphthous ulcer subtypes. RAS is a potentially debilitating condition and therefore its early diagnosis and appropriate management are key issues in the care of patients with this disease, both in primary and secondary care settings.</p><p>The authors of this...]]></description>
<dc:creator><![CDATA[Scully, C., Cowie, R.]]></dc:creator>
<dc:date>2012-05-14T02:00:55-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100709</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100709</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Pain (neurology), Dentistry and oral medicine]]></dc:subject>
<dc:title><![CDATA[Topical dexamethasone for recurrent aphthous ulceration reduces pain and size and increases healing with no significant adverse events]]></dc:title>
<prism:publicationDate>2012-05-14</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100388v1?rss=1">
<title><![CDATA[Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100388v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>There is some evidence for the role of inflammation and insulin resistance in the pathophysiology of plaque psoriasis. Thiazolidinediones are antidiabetic drugs that act by improving insulin sensitivity and also possess anti-inflammatory effects. Evidence from in vitro, animal and human studies has accumulated suggesting that these drugs may be of use in psoriasis.</p></sec><sec><st>Objective</st><p>This systematic review and meta-analysis was performed to assess the efficacy of thiazolidinediones on psoriasis severity.</p></sec><sec><st>Study selection</st><p>Randomised, open-label or single blind or double blind, published as well as unpublished, studies of thiazolidinedione administration compared with placebo, given to patients with plaque psoriasis for at least 8 weeks were considered for inclusion in this review. The primary outcomes were as follows: mean or mean percent change in Psoriasis Area and Severity Index (PASI) from baseline to end of treatment with pioglitazone, proportion of patients showing &gt;75% improvement in PASI score, and proportion of patients showing &gt;50% improvement in PASI score. Data analysis was done using Revman 5.</p></sec><sec><st>Findings</st><p>Twenty-seven relevant citations were identified. Two studies each for pioglitazone and rosiglitazone were included in the meta-analysis. There was a significantly greater mean decrease in PASI scores from baseline to end of treatment (&ndash;4.24 (95% CI &ndash;5.35 to &ndash;3.12)) in the pioglitazone group as compared to placebo. There was a non-significant improvement in PASI50/70 in the pooled analysis of rosiglitazone trials.</p></sec><sec><st>Conclusion</st><p>Pioglitazone appears to have efficacy for the treatment of psoriasis. The clinical significance of the effect and role in management of psoriasis deserve further study.</p></sec>]]></description>
<dc:creator><![CDATA[Malhotra, A., Shafiq, N., Rajagopalan, S., Dogra, S., Malhotra, S.]]></dc:creator>
<dc:date>2012-04-20T02:01:31-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100388</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100388</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Drugs: musculoskeletal and joint diseases, Dermatology]]></dc:subject>
<dc:title><![CDATA[Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis]]></dc:title>
<prism:publicationDate>2012-04-20</prism:publicationDate>
<prism:section>Systematic review</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100557v1?rss=1">
<title><![CDATA[Early umbilical cord clamping increases the risk of neonatal anaemia and infant iron deficiency]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100557v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Early cord clamping (ECC) has been practiced intermittently for over 100 years. However, it did not enter standard care until it was included, for convenience, as part of the package of active management of the third stage of labour (AMTSL). Since the 1980s, when the total package (oxytocic, controlled cord traction and early cord clamping) was shown to be effective at preventing postpartum haemorrhage (PPH,<cross-ref type="bib" refid="R1">1</cross-ref>), AMTSL has been vigorously promoted as a way of preventing maternal deaths.</p><p>It is only in the last decade that the AMSTL package has been unpacked and it is becoming clear that it is only the oxytocic drug that reduces PPH &ndash; the controlled cord traction2 and early cord clamping (ECC)3 appear to have no maternal benefits. But might ECC actually cause harm to the baby? In preterm births, there is evidence from a small number of randomised babies (n=297) that ECC causes...]]></description>
<dc:creator><![CDATA[Weeks, A.]]></dc:creator>
<dc:date>2012-04-19T02:01:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100557</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100557</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Rehabilitation medicine, Clinical trials (epidemiology), Haematology (incl blood transfusion), Contraception, Drugs: obstetrics and gynaecology, Pregnancy, Developmental paediatrics, Sports and exercise medicine]]></dc:subject>
<dc:title><![CDATA[Early umbilical cord clamping increases the risk of neonatal anaemia and infant iron deficiency]]></dc:title>
<prism:publicationDate>2012-04-19</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100673v1?rss=1">
<title><![CDATA[Catheter-directed thrombolysis prevents post-thrombotic syndrome in patients with acute deep vein thrombosis in the upper half of the thigh]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100673v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Post-thrombotic syndrome (PTS) can be a debilitating consequence of acute deep venous thrombosis (DVT). The subset of patients with iliofemoral DVT represents a particularly high-risk cohort of patients likely to develop PTS.<cross-ref type="bib" refid="R1">1</cross-ref> Anatomically, the common femoral, external iliac and common iliac veins represent the single venous outflow tract from the lower extremity and, when acutely occluded, result in high venous and compartment pressures.<cross-ref type="bib" refid="R2">2</cross-ref> Sustained venous hypertension, specifically ambulatory venous hypertension, is the underlying pathophysiology of chronic post-thrombotic venous disease.</p><p>Treatment strategies which eliminate clot and restore unobstructed venous drainage to the vena cava have resulted in better quality of life and reduced PTS<cross-ref type="bib" refid="R3">3</cross-ref> than anticoagulation alone.<cross-ref type="bib" refid="R4">4</cross-ref> Success of thrombus removal is associated with these outcomes. A well-designed randomised trial comparing catheter-directed thrombolysis (CDT) and anticoagulation versus anticoagulation alone for iliofemoral DVT has been eagerly awaited.</p></sec><sec id="s2"><st>Methods</st><p>The stated purpose of the CaVenT study...]]></description>
<dc:creator><![CDATA[Comerota, A. J.]]></dc:creator>
<dc:date>2012-04-17T02:03:38-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100673</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100673</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Drugs: cardiovascular system, Stroke, Hypertension, Venous thromboembolism, Radiology, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Catheter-directed thrombolysis prevents post-thrombotic syndrome in patients with acute deep vein thrombosis in the upper half of the thigh]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100570v1?rss=1">
<title><![CDATA[Multicondition collaborative care intervention for people with coronary heart disease and/or diabetes, depression and poor control of hypertension, blood sugar or hypercholesterolemia improves disability and quality of life compared with usual care]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100570v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Depression is two to three times more common in people with chronic physical disease. When combined with other chronic diseases, depression is associated with significantly greater decrements in functioning than one or more chronic physical illness, or depression alone.<cross-ref type="bib" refid="R1">1</cross-ref> Innovative collaborative care models have proven successful in reducing symptoms of depression in people with chronic disease<cross-ref type="bib" refid="R2">2</cross-ref> but the &lsquo;TEAMcare&rsquo; intervention is the first to improve depression and physical health in people with poorly controlled diabetes and/or coronary heart disease and poorly controlled blood pressure or cholesterol.<cross-ref type="bib" refid="R3">3</cross-ref> The paper by Von Korff and colleagues suggests that as well as reducing depression and improving disease control, multicondition collaborative care can also reduce social role disability and improve quality of life (QOL) in people with chronic disease, thereby promoting healthy ageing.</p></sec><sec id="s2"><st>Methods</st><p>The TEAMcare study randomised 214 patients with depression and poorly controlled diabetes and/or coronary heart...]]></description>
<dc:creator><![CDATA[Coventry, P.]]></dc:creator>
<dc:date>2012-04-17T02:03:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100570</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100570</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Drugs: cardiovascular system, Hypertension, Ischaemic heart disease, Diabetes, Lipid disorders]]></dc:subject>
<dc:title><![CDATA[Multicondition collaborative care intervention for people with coronary heart disease and/or diabetes, depression and poor control of hypertension, blood sugar or hypercholesterolemia improves disability and quality of life compared with usual care]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100538v1?rss=1">
<title><![CDATA[Of 3700 children thought to have non-cardiac chest pain at initial paediatric cardiology clinic evaluation, none suffered cardiac death over a median of 4 years follow-up]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100538v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Chest pain (CP) in children is a common complaint, though cardiac causes are rare. The study by Saleeb <I>et al</I> aims to determine whether any children diagnosed initially with CP in the cardiology clinic of a children's hospital subsequently died as a result of a cardiac condition.</p></sec><sec id="s2"><st>Methods</st><p>Medical records were reviewed for all clinic patients &gt;6 years of age with an International Classification of Diseases-9 (ICD-9) code for initial CP assessment who were seen at Children's Hospital Boston over 10 years. The authors suggest that usual coding practice in the clinic would be to use such codes for patients not considered to have cardiac disease. Demographic features, history and exam findings, tests performed and presumed diagnoses were abstracted. The vital status of all patients, and cause of death of deceased patients, were ascertained from the National Death Index and the Social Security Death Index.</p><p>The primary outcome was death related...]]></description>
<dc:creator><![CDATA[Thull-Freedman, J.]]></dc:creator>
<dc:date>2012-04-17T02:03:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100538</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100538</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Drugs: cardiovascular system, Heart failure, Pain (neurology), Stroke, Child and adolescent psychiatry, Suicide (psychiatry), Radiology, Clinical diagnostic tests, Radiology (diagnostics), Screening (epidemiology), Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Of 3700 children thought to have non-cardiac chest pain at initial paediatric cardiology clinic evaluation, none suffered cardiac death over a median of 4 years follow-up]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Prognosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100574v1?rss=1">
<title><![CDATA[Children with minor blunt head trauma, a Glasgow Coma Scale score of 14 or 15 and a normal CT scan are at very low risk of traumatic findings on subsequent neuroimaging or of requiring neurosurgical intervention]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100574v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Mild traumatic brain injuries (TBIs) are common in children and the vast majority of children with mild TBI have normal head CT scans. However, even when the initial scan is normal, some patients are reimaged and/or hospitalised for observation. There is little data regarding the value or harm of a second scan or hospitalisation and one would like to avoid the radiation and costs of these interventions if they are not beneficial. The study by Holmes <I>et al</I> is a secondary analysis of a large study of mild paediatric TBI designed to identify children who do not need a head CT.<cross-ref type="bib" refid="R1">1</cross-ref> The objective of the current study was to identify the frequency of neurologic complications (defined as neurosurgical intervention or subsequent abnormal neuroimaging results) in children with minor blunt head trauma and a normal initial CT scan.</p></sec><sec id="s2"><st>Methods</st><p>This was a planned secondary analysis of data from a...]]></description>
<dc:creator><![CDATA[Blume, H. K.]]></dc:creator>
<dc:date>2012-04-17T02:03:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100574</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100574</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Radiology, Clinical diagnostic tests, Radiology (diagnostics), Injury]]></dc:subject>
<dc:title><![CDATA[Children with minor blunt head trauma, a Glasgow Coma Scale score of 14 or 15 and a normal CT scan are at very low risk of traumatic findings on subsequent neuroimaging or of requiring neurosurgical intervention]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Prognosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100562v1?rss=1">
<title><![CDATA[Acute conjunctivitis in primary care: antibiotics and placebo associated with small increase in the proportion cured by 7 days compared with no treatment]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100562v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Acute infective conjunctivitis is the commonest ocular problem encountered in general practice. Traditionally most patients were prescribed topical antibiotics, essentially to cover for bacterial causes. Despite some evidence of improved clinical and microbiological remission rates with antibiotic use in bacterial conjunctivitis, most patients with acute infective conjunctivitis will get better without antibiotics.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> Viral infections are more common than bacterial, especially in adults, and are usually self-limiting.<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3">3</cross-ref> With this knowledge, prescribing guidance has changed in the last decade and suggests delayed or deferred use of topical antibiotics.<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R4">4</cross-ref> &lsquo;Over-the-counter&rsquo; chloramphenicol risks unnecessary treatment and delayed diagnosis of alternative conditions.</p></sec><sec id="s2"><st>Methods</st><p>The authors conducted an individual patient level meta-analysis of data from three randomised clinical trials. Studies were identified by literature search and selected for inclusion, by two independent assessors, if the following criteria were met: (i)...]]></description>
<dc:creator><![CDATA[Steeples, L., Mercieca, K.]]></dc:creator>
<dc:date>2012-04-17T02:03:36-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100562</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100562</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[General practice / family medicine, Ophthalmology]]></dc:subject>
<dc:title><![CDATA[Acute conjunctivitis in primary care: antibiotics and placebo associated with small increase in the proportion cured by 7 days compared with no treatment]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100677v1?rss=1">
<title><![CDATA[The legacy effect: 4.5 years of a chlorthalidone-based antihypertensive regimen reduces cardiovascular mortality and prolongs cardiovascular disease-free survival at 22 years for older patients with isolated systolic hypertension]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100677v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Due to decreased vascular compliance, hypertension in older patients is commonly limited to systolic blood pressure; pulse pressures are wider than for younger patients. Decades ago, physicians commonly withheld treatment for older patients with isolated systolic hypertension due to a belief that this was a &lsquo;normal&rsquo; or acceptable consequence of ageing that carried no excess morbidity. Since the early 1990's, multiple large-scale treatment trials disproved this hypothesis. These included the Syst-Eur and Syst-China trials of nitrendipine, and the MRC(Medical Research Council) trial of hydrochlorothiazide plus amiloride.</p><p>One of the largest and most influential trials was the Systolic Hypertension in the Elderly Program (SHEP) study.<cross-ref type="bib" refid="R1">1</cross-ref> In this trial, eligible patients were above the age of 60 (mean 71.6 years), had no pre-existing cardiovascular disease, and had baseline systolic blood pressures of 160 to 219 mm Hg and diastolic blood pressures of less than 90 mm Hg. Patients were randomly...]]></description>
<dc:creator><![CDATA[Smetana, G. W.]]></dc:creator>
<dc:date>2012-04-17T02:03:36-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100677</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100677</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, General practice / family medicine, Drugs: cardiovascular system, Stroke, Hypertension, Ischaemic heart disease]]></dc:subject>
<dc:title><![CDATA[The legacy effect: 4.5 years of a chlorthalidone-based antihypertensive regimen reduces cardiovascular mortality and prolongs cardiovascular disease-free survival at 22 years for older patients with isolated systolic hypertension]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100631v1?rss=1">
<title><![CDATA[Low-molecular-weight heparin prophylaxis does not affect mortality in acutely ill medical patients at low risk for venous thromboembolism]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100631v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Pharmacological thromboprophylaxis has been proven effective for preventing venous thromboembolic events (VTE) in both surgical and acutely ill medical patients.<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3">3</cross-ref> Even though clinical guidelines recommend its use in both patient populations, thromboprophylaxis is more frequently used in surgical patients.<cross-ref type="bib" refid="R4">4</cross-ref> This could be due to a lack of evidence for a mortality reduction associated with pharmacological thromboprophylaxis in acutely ill medical patients, even when data are pooled together in a meta-analysis.<cross-ref type="bib" refid="R5">5</cross-ref></p></sec><sec id="s2"><st>Methods</st><p>This study is an international multi-centre double-blind, placebo-controlled, randomised trial comparing enoxaparin 40 mg daily for 10&plusmn;4 days compared with placebo in 8392 patients mainly from Asia. All patients received knee-high elastic stockings with graduated compression. Inclusion criteria were an age of at least 40 years and hospitalisation for acute decompensated heart failure, severe systemic infection with at least one risk factor for VTE, or active cancer. The primary...]]></description>
<dc:creator><![CDATA[Sjalander, A.]]></dc:creator>
<dc:date>2012-04-17T02:03:36-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100631</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100631</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Drugs: cardiovascular system, Guidelines]]></dc:subject>
<dc:title><![CDATA[Low-molecular-weight heparin prophylaxis does not affect mortality in acutely ill medical patients at low risk for venous thromboembolism]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100634v1?rss=1">
<title><![CDATA[Self-monitoring of oral anticoagulation reduces thromboembolic events and does not increase risk of bleeding in selected patients and settings]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100634v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Although oral anticoagulation with vitamin K antagonists reduces major thromboembolism in high-risk patients, it requires frequent laboratory monitoring to prevent over-anticoagulation which can result in serious bleeding or under anticoagulation which increases the risk for thromboembolism. This monitoring typically occurs in clinical settings, but with marketing of accurate and reliable portable devices, it can now be done more conveniently by the patient at home. Several clinical trials have evaluated the safety and efficacy of patient self-monitoring: either patient self-management (patient tests and adjusts the dose as needed) or patient self-testing with clinical dosing (dosing changes determined by clinicians). Heneghan <I>et al</I> present a systematic review and meta-analysis of individual patient data from 11 of these trials.</p></sec><sec id="s2"><st>Methods</st><p>A systematic review of published and unpublished sources identified 21 trials published in any language that randomised adults to either usual care or patient self-monitoring. Ten studies were excluded because individual patient level...]]></description>
<dc:creator><![CDATA[Bloomfield, H.]]></dc:creator>
<dc:date>2012-04-17T02:03:36-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100634</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100634</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ophthalmology, Arrhythmias]]></dc:subject>
<dc:title><![CDATA[Self-monitoring of oral anticoagulation reduces thromboembolic events and does not increase risk of bleeding in selected patients and settings]]></dc:title>
<prism:publicationDate>2012-04-17</prism:publicationDate>
<prism:section>Therapeutics/Prevention</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100287v1?rss=1">
<title><![CDATA[Systematic reviews to evaluate causation: an overview of methods and application]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100287v1?rss=1</link>
<description><![CDATA[<p>Currently systematic reviews focus on diagnosis or effectiveness of treatment. It is the understanding of disease aetiology that underpins medical education, practice and research. Whether an association meets causal criteria is usually assessed qualitatively. However, this can also be examined through evidence synthesis and systematic reviews to evaluate disease causation and mechanisms are much needed. It is important in such a review to specify the questions to be addressed regarding causal criteria such as strength, consistency, temporality, specificity, biological gradient, plausibility and experimental evidence. The next step is to conduct a thorough literature search to identify the relevant studies and to assess them for their quality, particularly in relation to the risk of bias, ascertainment of exposures and ascertainment of outcomes. Data synthesis can then examine if the observed associations in collated studies are consistent, strong and temporal using techniques such as meta-analysis, testing for heterogeneity and meta-regression. Biological plausibility and coherence with existing theories can also be examined systematically through an assessment of the basic scientific literature. Experimental evidence might also be collated and synthesised to determine if removal of a causal agent alters the outcome. Through these steps a systematic review can help to establish whether an association is causal or not.</p>]]></description>
<dc:creator><![CDATA[Khan, K. S., Ball, E., Fox, C. E., Meads, C.]]></dc:creator>
<dc:date>2012-04-05T02:02:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100287</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100287</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Medical education, Medical humanities]]></dc:subject>
<dc:title><![CDATA[Systematic reviews to evaluate causation: an overview of methods and application]]></dc:title>
<prism:publicationDate>2012-04-05</prism:publicationDate>
<prism:section>Methods</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100515v1?rss=1">
<title><![CDATA[In people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100515v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Osteoarthritis of the finger joints is present in about 10% of individuals aged 40 to 49, rising to 92% in individuals over 70 years of age.<cross-ref type="bib" refid="R1">1</cross-ref> However, knowledge and research in the field of hand osteoarthritis are limited. Therefore, the Disease Characteristics in Hand OA initiative was founded in 2005 with the aim of addressing key issues and facilitating research into hand osteoarthritis. This group concluded that future research in hand osteoarthritis is warranted.<cross-ref type="bib" refid="R2">2</cross-ref> Whereas several studies were conducted over the last two decades exploring the ability of chemical entities to induce symptom or structure modifications in osteoarthritis of the lower limbs,<cross-ref type="bib" refid="R3">3</cross-ref><cross-ref type="bib" refid="R4">&ndash;</cross-ref><cross-ref type="bib" refid="R5">5</cross-ref> few studies were conducted with improvement in hand osteoarthritis symptoms, or structure as outcomes.</p></sec><sec id="s2"><st>Methods</st><p>Gabay and colleagues conducted a single-centre, randomised, double-blind, placebo-controlled clinical trial of 162 patients with radiographic evidence of hand osteoarthritis and moderate to...]]></description>
<dc:creator><![CDATA[Reginster, J.-Y.]]></dc:creator>
<dc:date>2012-04-05T02:02:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100515</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100515</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Pain (neurology), Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Osteoarthritis]]></dc:subject>
<dc:title><![CDATA[In people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo]]></dc:title>
<prism:publicationDate>2012-04-05</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100509v2?rss=1">
<title><![CDATA[Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100509v2?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Effective pharmacological prophylaxis reduces venous thromboembolism (VTE) in high-risk medically-ill patients.<cross-ref type="bib" refid="R1">1</cross-ref> But the net benefit of VTE prevention strategies in unselected medical patients is not established.</p></sec><sec id="s2"><st>Methods</st><p>Lederle <I>et al</I> conducted a comprehensive meta-analysis of available clinical trials. Articles were identified by searching MEDLINE from 1950 through April 2011 and the Cochrane Library. A comprehensive search strategy was provided including details of searches for unpublished material, with good attention to study quality and a data extraction protocol. Studies providing separate data for medical patients or stroke patients in acute or intermediate care, healthcare facilities were included. The analysis included data from randomised trials that provided clinical outcomes and evaluated therapy with heparins or mechanical devices. Studies were included if they compared these treatments to no treatment, or to other active interventions. The principal outcome was 120-day total mortality. Secondary outcomes included symptomatic deep vein thrombosis (DVT), symptomatic pulmonary...]]></description>
<dc:creator><![CDATA[Crowther, M., Garcia, D. G.]]></dc:creator>
<dc:date>2012-04-04T02:02:04-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100509</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100509</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Venous thromboembolism, Pulmonary embolism]]></dc:subject>
<dc:title><![CDATA[Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit]]></dc:title>
<prism:publicationDate>2012-04-04</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100433v2?rss=1">
<title><![CDATA[Population benefits of HPV vaccination for boys: a complex equation]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100433v2?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>With the licensing and subsequent roll-out of female vaccination against human papillomavirus (HPV) in many, mainly high-resource settings, there has emerged a chorus of voices advocating vaccination for males. The interest in male vaccination has intensified with the publication of early observational data from Australia heralding the effectiveness of vaccination when high coverage is achieved<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> and the results of clinical trials demonstrating efficacy against infection and disease in males.<cross-ref type="bib" refid="R3">3</cross-ref> A recent mathematical modelling study by Brisson <I>et al</I> provides estimates of the potential long-term benefits of HPV vaccination, including the incremental benefit of adding male vaccination to an existing female-only programme.</p></sec><sec id="s2"><st>Methods</st><p>A previously described<cross-ref type="bib" refid="R4">4</cross-ref> individual-based transmission-dynamic model was developed and calibrated to sexual behaviour and HPV epidemiological data for Canada. The effect of vaccination was measured in terms of the relative reduction in HPV prevalence at equilibrium compared with no...]]></description>
<dc:creator><![CDATA[Regan, D. G.]]></dc:creator>
<dc:date>2012-04-03T02:00:49-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100433</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100433</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Vaccination programs, Immunology (including allergy), Vaccination / immunisation, Health education]]></dc:subject>
<dc:title><![CDATA[Population benefits of HPV vaccination for boys: a complex equation]]></dc:title>
<prism:publicationDate>2012-04-03</prism:publicationDate>
<prism:section>Prevention</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100549v1?rss=1">
<title><![CDATA[For women with term low-risk pregnancies, risk of perinatal mortality and intrapartum morbidity similar across planned places of birth]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100549v1?rss=1</link>
<description><![CDATA[<p>Commentary on: <bib><other-ref>Birthplace in England Collaborative Group. Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England national prospective cohort study. <I><title>BMJ</title></I> <date>2011</date>;<b><volume-nr>343</volume-nr></b>:<first-page>d7400</first-page>.</other-ref></bib></p>]]></description>
<dc:creator><![CDATA[Janssen, P. A.]]></dc:creator>
<dc:date>2012-04-02T02:01:44-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100549</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100549</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Pregnancy]]></dc:subject>
<dc:title><![CDATA[For women with term low-risk pregnancies, risk of perinatal mortality and intrapartum morbidity similar across planned places of birth]]></dc:title>
<prism:publicationDate>2012-04-02</prism:publicationDate>
<prism:section>Aetiology/Harm</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100672v1?rss=1">
<title><![CDATA[Serial changes in highly sensitive cardiac troponin improve the early diagnosis of acute myocardial infarction]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100672v1?rss=1</link>
<description><![CDATA[<p>Commentary on: <bib><other-ref><firstauthor><snm>Keller</snm> <fnm>T</fnm></firstauthor>, Zeller T, Ojeda F, <I>et al</I>.. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. <I><title>JAMA</title></I> <date>2011</date>;<b><volume-nr>306</volume-nr></b>:<first-page>2684</first-page>&ndash;93.</other-ref></bib></p>]]></description>
<dc:creator><![CDATA[Reichlin, T., Mueller, C.]]></dc:creator>
<dc:date>2012-04-02T02:01:44-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100672</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100672</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Drugs: cardiovascular system, Ischaemic heart disease]]></dc:subject>
<dc:title><![CDATA[Serial changes in highly sensitive cardiac troponin improve the early diagnosis of acute myocardial infarction]]></dc:title>
<prism:publicationDate>2012-04-02</prism:publicationDate>
<prism:section>Diagnosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100564v1?rss=1">
<title><![CDATA[For people with persistent tension-type neck pain, a multicomponent pain and stress self-management intervention gives better improvement in ability to control pain and self-efficacy, but not disability, than physical therapy]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100564v1?rss=1</link>
<description><![CDATA[<p>Commentary on: <bib><other-ref><firstauthor><snm>Gustavsson</snm> <fnm>C</fnm></firstauthor>, Denison E, von Koch L. Self-management of persistent neck pain: two-year follow-up of a randomized controlled trial of a multicomponent group intervention in primary health care. <I><title>Spine</title></I> <date>2011</date>;<b><volume-nr>36</volume-nr></b>:<first-page>2105</first-page>&ndash;15.</other-ref></bib></p>]]></description>
<dc:creator><![CDATA[Pollard, H.]]></dc:creator>
<dc:date>2012-04-02T02:01:43-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100564</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100564</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Rehabilitation medicine, Clinical trials (epidemiology), General practice / family medicine, Pain (neurology), Sports and exercise medicine]]></dc:subject>
<dc:title><![CDATA[For people with persistent tension-type neck pain, a multicomponent pain and stress self-management intervention gives better improvement in ability to control pain and self-efficacy, but not disability, than physical therapy]]></dc:title>
<prism:publicationDate>2012-04-02</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100571v1?rss=1">
<title><![CDATA[In China, hospital births are associated with a 62% decreased risk of neonatal mortality]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100571v1?rss=1</link>
<description><![CDATA[<p>Commentary on: <bib><other-ref><firstauthor><snm>Feng</snm> <fnm>XL</fnm></firstauthor>, Guo S, Hipgrave D, <I>et al</I>.. China's facility-based birth strategy and neonatal mortality: a population-based epidemiological study. <I><title>Lancet</title></I> <date>2011</date>;<b><volume-nr>378</volume-nr></b>:<first-page>1493</first-page>&ndash;500.</other-ref></bib></p>]]></description>
<dc:creator><![CDATA[Wax, J. R.]]></dc:creator>
<dc:date>2012-04-02T02:01:43-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100571</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100571</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies]]></dc:subject>
<dc:title><![CDATA[In China, hospital births are associated with a 62% decreased risk of neonatal mortality]]></dc:title>
<prism:publicationDate>2012-04-02</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100632v1?rss=1">
<title><![CDATA[Higher breastfeeding intensity associated with improved postpartum glucose metabolism in women with recent gestational diabetes]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100632v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>WHO recommends that all babies should be exclusively breastfed for the first 6 months after birth.<cross-ref type="bib" refid="R1">1</cross-ref> In the general population, breastfeeding has been associated with short-term improvement in postpartum maternal glucose metabolism and long-term reduction in risk of cardiometabolic disease including type 2 diabetes (T2DM) and myocardial infarction.<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> Women diagnosed with gestational diabetes mellitus (GDM), defined as glucose intolerance of varying severity with onset and first recognition in pregnancy, have an increased lifetime risk of developing both T2DM and cardiovascular disease.<cross-ref type="bib" refid="R4">4</cross-ref> However, the relationship between breastfeeding and maternal glucose metabolism has not been clearly established in this high-risk population. It is in this context that Gunderson <I>et al</I> have explored the association between lactation intensity and postpartum metabolism in women with recent GDM.</p></sec><sec id="s2"><st>Methods</st><p>The authors analysed 522 women with recent GDM recruited between September 2008 and March 2011, who underwent...]]></description>
<dc:creator><![CDATA[Borgono, C. A., Retnakaran, R.]]></dc:creator>
<dc:date>2012-03-29T02:01:14-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100632</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100632</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Genetics, Drugs: cardiovascular system, Childhood nutrition, Diet, Pregnancy, Ischaemic heart disease, Diabetes]]></dc:subject>
<dc:title><![CDATA[Higher breastfeeding intensity associated with improved postpartum glucose metabolism in women with recent gestational diabetes]]></dc:title>
<prism:publicationDate>2012-03-29</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100584v1?rss=1">
<title><![CDATA[Response to Drs Hoberman and Paradise]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100584v1?rss=1</link>
<description><![CDATA[<p>We thank Drs Hoberman and Paradise for writing to highlight areas of disagreement and for pointing out a couple of minor errors in our commentary.</p><p>Our commentary was a comparison between the paper by Hoberman, Paradise <I>et al</I>, and one by Tahtinen <I>et al</I> in the same issue of the <I>New England Journal of Medicine</I>. Because of space limitations, we focused only on the primary outcomes of both studies. The primary outcome of the study by Hoberman <I>et al</I> was symptomatic response.</p><p>In their letter, Hoberman and Paradise suggest that overall clinical response, which in their study differed more between groups but was largely based on otoscopic findings, is more important. We disagree. In assessing the magnitude of benefit of antibiotics for acute otitis media (AOM) in studies such as this one, we feel that clinicians should consider symptomatic response as the most important outcome, for three reasons: (1) shortened symptom duration...]]></description>
<dc:creator><![CDATA[Marmor, A., Newman, T.]]></dc:creator>
<dc:date>2012-03-22T02:03:42-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100584</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100584</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:title><![CDATA[Response to Drs Hoberman and Paradise]]></dc:title>
<prism:publicationDate>2012-03-22</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100424v1?rss=1">
<title><![CDATA[In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100424v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal (GI) tract characterised by abdominal pain or discomfort, associated with a change in either frequency, or form of stool. The condition is chronic, with a relapsing and remitting natural history,<cross-ref type="bib" refid="R1">1</cross-ref> and affects up to one in five people in the general population. IBS represents a significant economic burden to the health service, and there is no known structural cause to explain the symptoms that sufferers report. Therapy is therefore directed towards relief, or improvement, of symptoms. However, there remains controversy about which treatments are effective.</p></sec><sec id="s2"><st>Methods</st><p>Ruepert <I>et al</I> searched MEDLINE, EMBASE, the Cochrane Library, CINAHL and PsycInfo between 1966 and March 2009 to identify randomised controlled trials (RCTs) published in full that recruited IBS sufferers aged over 12 years, and compared efficacy of soluble and insoluble fibre, antispasmodics (including peppermint oil), or antidepressants with placebo. Studies...]]></description>
<dc:creator><![CDATA[Ford, A. C.]]></dc:creator>
<dc:date>2012-03-22T02:03:42-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100424</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100424</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Neurogastroenterology, Clinical trials (epidemiology), Drugs: CNS (not psychiatric), Pain (neurology), Drugs: musculoskeletal and joint diseases]]></dc:subject>
<dc:title><![CDATA[In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents]]></dc:title>
<prism:publicationDate>2012-03-22</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100440v1?rss=1">
<title><![CDATA[Number needed to screen to detect adenomas, advanced adenomas and colorectal cancer is higher in women than in similarly aged men]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100440v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>A total of 1.2 million cases of colorectal cancer (CRC) and nearly 609 000 related deaths will occur worldwide this year.<cross-ref type="bib" refid="R1">1</cross-ref> CRC screening decreases CRC incidence and mortality.<cross-ref type="bib" refid="R2">2</cross-ref> Unfortunately, colonoscopy has been shown to be less effective in CRC control than previously considered<cross-ref type="bib" refid="R3">3</cross-ref> and CRC occurs in up to 9% of individuals undergoing colonoscopy in the preceding 9 years<cross-ref type="bib" refid="R4">4</cross-ref>. Factors associated with interval CRC include lower completion and polypectomy rates.</p><p>Colonoscopy is often considered the preferred CRC screening test. Many countries including Austria recommend initiating screening colonoscopy in average risk individuals at age 50, one decade earlier than the typical onset of CRC.</p><p>The objective of this study by Frelitsch <I>et al</I> is to determine the prevalence of adenomas, advanced adenomas (AA) and CRC detected on screening colonoscopy and the number needed to screen (NNS) by 5 year age groups and by gender....]]></description>
<dc:creator><![CDATA[Burke, C. A.]]></dc:creator>
<dc:date>2012-03-22T02:03:42-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100440</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100440</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Obesity (nutrition), Screening (oncology), Surgical diagnostic tests, Screening (epidemiology), Health education, Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Number needed to screen to detect adenomas, advanced adenomas and colorectal cancer is higher in women than in similarly aged men]]></dc:title>
<prism:publicationDate>2012-03-22</prism:publicationDate>
<prism:section>Diagnosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100555v1?rss=1">
<title><![CDATA[Lifestyle modifications and pharmacotherapy for cardiovascular risk factors are associated with improvements in erectile dysfunction]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100555v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Pharmacotherapies directly targeted towards the pathophysiology of erectile dysfunction (ED) are efficacious. But whether lifestyle modification and other pharmacotherapies that target one of the main underlying risks for ED, cardiovascular (CV) risk factors and disease can improve ED remains unclear.</p></sec><sec id="s2"><st>Methods</st><p>An online search of peer-reviewed databases was conducted for randomised controlled clinical trials of lifestyle modification or pharmacotherapy of CV risk factors with a minimum intervention period of 6 weeks. Study selection was undertaken with a hierarchical approach by two of the authors acting independently.</p><p>Erectile function was assessed with the 5-item International Index of Erectile Function (IIEF-5) questionnaire. Intervention outcome was measured by a change in the IIEF-5 score, and the weighted mean difference with 95% CIs was calculated using a random effects model. Statistical analyses included the assessment of heterogeneity and publication bias.</p></sec><sec id="s3"><st>Findings</st><p>Of the 1943 references retrieved, six studies satisfied the selection criteria. Four of these involved...]]></description>
<dc:creator><![CDATA[Chew, K.-K.]]></dc:creator>
<dc:date>2012-03-14T02:03:08-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100555</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100555</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Journalology, Smoking and tobacco, Clinical trials (epidemiology), Epidemiologic studies, Drugs: CNS (not psychiatric), Stroke, Diet, Sexual and gender disorders, Sexual dysfunction, Vulvovaginal disorders, Alcohol, Health education, Smoking]]></dc:subject>
<dc:title><![CDATA[Lifestyle modifications and pharmacotherapy for cardiovascular risk factors are associated with improvements in erectile dysfunction]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100452v1?rss=1">
<title><![CDATA[In reference to: amoxicillin-clavulanate improves symptoms, reduces treatment failure in select children with acute otitis media and increases risk of diarrhoea]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100452v1?rss=1</link>
<description><![CDATA[<p>In their commentary<cross-ref type="bib" refid="R1">1</cross-ref> about our report<cross-ref type="bib" refid="R2">2</cross-ref> and a similar Finnish report<cross-ref type="bib" refid="R3">3</cross-ref> on the treatment of acute otitis media in young children, Drs Marmor and Newman ignored or misread crucial elements. Although the commentary was aptly titled, &lsquo;Amoxicillin-clavulanate improves symptoms, reduces treatment failure in select children with acute otitis media...,&rsquo; the text applicable to our trial was limited to a discussion of the differences we found between the amoxicillin-clavulanate and placebo treatment groups in symptomatic response, without reference to differences we found in rates of clinical failure.</p><p>As stated in our report, we ourselves considered the differences in symptomatic response between the amoxicillin-clavulanate and placebo groups to be modest. On the other hand, the differences we found in rates of clinical failure, as manifested by persistence of otoscopic signs of infection, were substantial: at or before day 4&ndash;5, 4% versus 23% (absolute difference 19%; 95% CI...]]></description>
<dc:creator><![CDATA[Hoberman, A., Paradise, J. L.]]></dc:creator>
<dc:date>2012-03-14T02:03:09-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100452</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100452</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:title><![CDATA[In reference to: amoxicillin-clavulanate improves symptoms, reduces treatment failure in select children with acute otitis media and increases risk of diarrhoea]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100450v1?rss=1">
<title><![CDATA[Is recent advice on exclusive breastfeeding consistent with the data presented?]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100450v1?rss=1</link>
<description><![CDATA[<p>Dear Editor,</p><p>We read with concern the commentary by Binns CW<cross-ref type="bib" refid="R1">1</cross-ref> on the paper by Huh SY.<cross-ref type="bib" refid="R2">2</cross-ref> After reiterating the WHO recommendation to breastfeed exclusively for 6 months Binns writes; "These results are consistent with this recommendation...."</p><p>Our analysis of the data in <cross-ref type="fig" refid="F1">figure 1</cross-ref> suggests different conclusions.</p><p>The original authors studied obesity rates at 3 years and feeding patterns in the first 6 months of life.</p><p>They showed;</p><p><l type="tab"><li><p> Breastfeeding for 4 months or more is associated with low rates of obesity at 3 years.</p></li><li><p> Lower rates of obesity are associated with any proportion of breast milk.</p></li><li><p> The data does not identify infants exclusively breastfed.</p></li><li><p> For babies in whom breastfeeding has ceased by 4 months, starting solids between 4 and 5 months is associated with equally low rates of obesity at 3 years.</p></li><li><p> Ceasing breastfeeding while also commencing solids before 4 months was associated with a significant...]]></description>
<dc:creator><![CDATA[Symon, B., Bammann, M.]]></dc:creator>
<dc:date>2012-03-14T02:03:09-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100450</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100450</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:title><![CDATA[Is recent advice on exclusive breastfeeding consistent with the data presented?]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100493v1?rss=1">
<title><![CDATA[Comment on 'A qualitative approach to Bayes' theorem' by Medow and Lucey]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100493v1?rss=1</link>
<description><![CDATA[<p>Dear editor,</p><p>We welcome the publication of Medow and Lucey in the December issue, describing a qualitative approach to Bayes' theorem.<cross-ref type="bib" refid="R1">1</cross-ref> Especially because the authors provide a new impulse to the development of clinician-friendly strategies for teaching clinical decision-making skills.</p><p>However, the approach proposed by the authors is not new. We reported a didactic model based on a visual representation of Bayesian logic on a logarithmic scale 8 years ago in peer-reviewed journals.<cross-ref type="bib" refid="R2">2</cross-ref><cross-ref type="bib" refid="R3">&ndash;</cross-ref><cross-ref type="bib" refid="R4">4</cross-ref> Our logical frame is also categorical and similar to the one proposed here, but it is more elaborate: it allows for the extremes of the probability scale, it provides more test power categories, and it covers asymmetry of test results.</p><p>The authors report a major limitation of their model: it applies to the intermediate range of probabilities (10&ndash;90), leaving the very high post-test probabilities often at stake in specialist care and the...]]></description>
<dc:creator><![CDATA[Henriquez, A. R., Moreira, J., Van den Ende, J.]]></dc:creator>
<dc:date>2012-03-14T02:03:09-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100493</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100493</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:title><![CDATA[Comment on 'A qualitative approach to Bayes' theorem' by Medow and Lucey]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>Letters</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100265v1?rss=1">
<title><![CDATA[Mechanisms of reducing postoperative pain, nausea and vomiting: a systematic review of current techniques]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100265v1?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Multimodal recovery programmes decrease hospital stay. The objective of this systematic review was to assess how single-modality evidence-based care principles, regarding postoperative analgesia and postoperative nausea and vomiting (PONV) prophylaxis, combine to achieve this.</p></sec><sec><st>Methods</st><p>A systematic review of randomised controlled trials was performed. Relevant trials compared postoperative epidural analgesia/parenteral opioid analgesia/paracetamol/non-steroidal anti-inflammatory drugs (NSAIDs) and postoperative antiemetics. The effect on recovery was evaluated in terms of length of hospital stay, pain intensity, duration of gastrointestinal dysfunction and incidence of PONV.</p></sec><sec><st>Results</st><p>Twenty-three trials were included. Epidural anaesthesia failed to reduce length of stay or the incidence of PONV when compared to controls. Pain intensity and time to first bowel movement were reduced (p&lt;0.05). Paracetamol did not reduce the incidence of PONV. NSAIDs reduced postoperative opioid consumption and the incidence of PONV (p&lt;0.05). Dexamethasone and 5-HT3 antagonists reduced the incidence of PONV compared to controls.</p></sec><sec><st>Conclusions</st><p>Epidural anaesthesia appears to not reduce length of hospital stay or incidence of PONV despite reducing pain intensity and ileus. NSAIDs are more effective than paracetamol in reducing postoperative opioid consumption and PONV, while dexamethasone and 5-HT3 antagonists are both effective in reducing PONV.</p></sec>]]></description>
<dc:creator><![CDATA[Rawlinson, A., Kitchingham, N., Hart, C., McMahon, G., Ling Ong, S., Khanna, A.]]></dc:creator>
<dc:date>2012-03-14T02:03:09-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100265</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100265</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Drugs: gastrointestinal system, Clinical trials (epidemiology), Pain (neurology), Pain (palliative care), Pain (anaesthesia), Drugs: musculoskeletal and joint diseases]]></dc:subject>
<dc:title><![CDATA[Mechanisms of reducing postoperative pain, nausea and vomiting: a systematic review of current techniques]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>Systemic review</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100415v1?rss=1">
<title><![CDATA[Greater diabetes-care contact frequency is associated with more rapid achievement of care goals but interpretation of finding requires consideration of patient adherence and motivation]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100415v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Recommended revisit intervals for adults with diabetes or other chronic conditions are based largely on expert opinion due to lack of evidence to support specific recommendations. Without randomised trial data, analysis of observational data to assess the association of specific visit interval with care outcomes is a desirable approach.</p></sec><sec id="s2"><st>Methods</st><p>This retrospective cohort study includes 26 496 adults with diabetes and elevated A1c, blood pressure (BP) or low-density lipoprotein cholesterol (LDL) values who received diabetes care from primary care physicians from 2000 to 2009. The association of primary care contact frequency (any chart note, with or without face-to-face visit) with time to address control of haemoglobin A1c (A1c), BP or LDL was estimated using marginal Cox proportional hazards regression models and other methods.</p></sec><sec id="s3"><st>Findings</st><p>Mean time to reach A1c &lt;7% was 22.8 months, to reach LDL &lt;100 mg/dl was 25.6 months, and to reach BP &lt;130/85 mm Hg was 8.7 months....]]></description>
<dc:creator><![CDATA[O'Connor, P. J.]]></dc:creator>
<dc:date>2012-03-14T02:03:08-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100415</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100415</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, General practice / family medicine, Hypertension, Diabetes]]></dc:subject>
<dc:title><![CDATA[Greater diabetes-care contact frequency is associated with more rapid achievement of care goals but interpretation of finding requires consideration of patient adherence and motivation]]></dc:title>
<prism:publicationDate>2012-03-14</prism:publicationDate>
<prism:section>Prognosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100525v1?rss=1">
<title><![CDATA[Preterm infants receiving heel lance procedures have slightly lower pain scores and quicker time to return to baseline heart rate when held in kangaroo care by the mother than by the father]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100525v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Kangaroo care (KC) is the practice of skin-to-skin contact between a parent and their infant. Although initially introduced for low-birthweight infants in Columbia because of scarce resources and high-neonatal morbidity,<cross-ref type="bib" refid="R1">1</cross-ref> KC has been widely adopted in both underdeveloped and developed countries. Benefits include reduction in mortality, infection and hospital length of stay and improved breastfeeding and maternal&ndash;infant bonding.<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> KC has also been shown to reduce procedural pain,<cross-ref type="bib" refid="R4">4</cross-ref> but studies have focused on maternal rather than paternal KC. As fathers are increasingly actively participating in their infant's care, including provision of KC, it is important to determine whether paternal KC has the same effect on neonatal pain.</p></sec><sec id="s2"><st>Methods</st><p>This randomised crossover trial evaluated the analgesic effect of paternal vs maternal KC in 62 preterm (gestational age (GA) of 28&ndash;36 weeks) infants undergoing heel lance (HL). Infants were randomised to the order assignment...]]></description>
<dc:creator><![CDATA[Shah, V., Jefferies, A.]]></dc:creator>
<dc:date>2012-03-07T02:01:58-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100525</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100525</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Pain (neurology), Childhood nutrition, Pain (palliative care), Pain (anaesthesia), Drugs: musculoskeletal and joint diseases]]></dc:subject>
<dc:title><![CDATA[Preterm infants receiving heel lance procedures have slightly lower pain scores and quicker time to return to baseline heart rate when held in kangaroo care by the mother than by the father]]></dc:title>
<prism:publicationDate>2012-03-07</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100451v1?rss=1">
<title><![CDATA[In TIA or stroke patients with intracranial arterial stenosis, aggressive medical therapy was superior to percutaneous transluminal angioplasty and stenting for 30-day risk of further stroke or death]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100451v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Patients with a recent transient ischaemic attack (TIA) or ischaemic stroke attributed to 70&ndash;99% intracranial artery stenosis have a 23% of 1-year risk for subsequent stroke. Over the past decade, intracranial angioplasty and stenting (IAS) has increasingly been used, without convincing evidence of efficacy or rigorous assessment of safety. Stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) was a clinical trial that sought to determine whether IAS combined with intensive medical management (IMM) was superior to IMM alone in the prevention of stroke and death.</p></sec><sec id="s2"><st>Methods</st><p>Subjects were adults with 30&ndash;80 years of age, and had suffered a TIA or non-disabling stroke within 30 days of enrolment, attributed to an intracranial stenosis of 70&ndash;99% as documented by angiography or non-invasive study. Those &lt;50 years old had to have &ge;1 additional criteria (vascular risk factor, ischaemic event, revascularisation procedure or evidence of atherosclerosis in another arterial...]]></description>
<dc:creator><![CDATA[Darsaut, T., Raymond, J., Lanthier, S.]]></dc:creator>
<dc:date>2012-03-07T02:01:58-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100451</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100451</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Stroke, Interventional cardiology, Radiology, Clinical diagnostic tests, Radiology (diagnostics)]]></dc:subject>
<dc:title><![CDATA[In TIA or stroke patients with intracranial arterial stenosis, aggressive medical therapy was superior to percutaneous transluminal angioplasty and stenting for 30-day risk of further stroke or death]]></dc:title>
<prism:publicationDate>2012-03-07</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100481v1?rss=1">
<title><![CDATA[Cryotherapy for plantar warts more costly but no more effective than salicylic acid self-treatment]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100481v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Cutaneous warts are highly prevalent benign papillomas of the skin, of which plantar warts (verrucae plantaris) are the most common type. Most warts disappear spontaneously, but plantar warts can also be persistent and frequently cause discomfort. In the UK, almost 2 million people visit their general practitioner (GP) for cutaneous warts at a cost of &pound;40M per year.<cross-ref type="bib" refid="R1">1</cross-ref> A 2006 Cochrane systematic review of topical treatments for cutaneous warts concluded that available trials were of poor methodological quality, and that evidence on cryotherapy was contradictory whereas evidence on salicylic acid was more convincing.<cross-ref type="bib" refid="R2">2</cross-ref> Cockayne <I>et al</I> assessed the clinical effectiveness and cost-effectiveness of cryotherapy and salicylic acid for plantar warts.</p></sec><sec id="s2"><st>Methods</st><p>Patients aged 12 years and above with one or more plantar warts were recruited from 16 sites (podiatry outpatient clinics or GP practices). This pragmatic, multi-centred, randomised controlled trial compared liquid nitrogen cryotherapy each 14&ndash;21...]]></description>
<dc:creator><![CDATA[Bruggink, S. C., Assendelft, W. J. J.]]></dc:creator>
<dc:date>2012-02-29T02:01:09-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100481</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100481</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Rehabilitation medicine, Clinical trials (epidemiology), General practice / family medicine, Pain (neurology), Dermatology, Sports and exercise medicine]]></dc:subject>
<dc:title><![CDATA[Cryotherapy for plantar warts more costly but no more effective than salicylic acid self-treatment]]></dc:title>
<prism:publicationDate>2012-02-29</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2012-100522v1?rss=1">
<title><![CDATA[Asthma is associated with various perinatal risks, but not with preterm birth when it is actively managed during pregnancy]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2012-100522v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Asthma is a growing medical and public health concern, and is the most frequent respiratory disorder complicating pregnancy. Estimates from 2001 to 2003 National Health Interview Survey indicate that 8.8% of pregnant women had current asthma.<cross-ref type="bib" refid="R1">1</cross-ref> As has been observed in other population segments, asthma in pregnancy has been increasing over time.<cross-ref type="bib" refid="R1">1</cross-ref> In the last four decades, several studies have reported the adverse effects of asthma during pregnancy on infant and maternal outcomes.<cross-ref type="bib" refid="R2">2</cross-ref> The reported adverse outcomes for the most part are consistent, but varied by the study design as well as by whether or not pregnant women with asthma were actively managed.</p></sec><sec id="s2"><st>Methods</st><p>Murphy <I>et al</I> conducted a systematic review of articles published in English during the period 1975 and 2009. Only prospective or retrospective cohort studies that enrolled pregnant women with asthma as study subjects, and pregnant women without asthma as controls...]]></description>
<dc:creator><![CDATA[Demissie, K.]]></dc:creator>
<dc:date>2012-02-18T02:03:24-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2012-100522</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2012-100522</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Immunology (including allergy), Pregnancy, Asthma, Dentistry and oral medicine]]></dc:subject>
<dc:title><![CDATA[Asthma is associated with various perinatal risks, but not with preterm birth when it is actively managed during pregnancy]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100454v1?rss=1">
<title><![CDATA[Of people admitted within 2 h of mild/improving stroke, 31% do not receive rtPA, although many of these people have poor outcomes]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100454v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Few patients with acute ischaemic stroke receive intravenous recombinant tissue plasminogen activator (rtPA), with the main exclusion criterion being hospital arrival after 41/2 h.<cross-ref type="bib" refid="R1">1</cross-ref> The second most common exclusion criterion from rtPA treatment, which is present in approximately 1/3 of all patients, is a mild or rapidly improving syndrome, termed &lsquo;too good to treat&rsquo;.<cross-ref type="bib" refid="R2">2</cross-ref> Uncertainty remains as to whether these patients should be thrombolysed as they may improve without treatment thus avoiding potential haemorrhagic complications. Others have noted that approximately 25% of &lsquo;too good to treat&rsquo; patients will go on to have a poor outcome.<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> The study by Smith <I>et al</I> examined the outcomes among untreated, as well as treated, patients with mild or rapidly improving strokes.</p></sec><sec id="s2"><st>Methods</st><p>Patients from Get with the Guidelines Stroke Program (a registry of stroke patients admitted to participating hospitals in the USA) between 2003 and...]]></description>
<dc:creator><![CDATA[Willey, J. Z.]]></dc:creator>
<dc:date>2012-02-18T02:03:24-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100454</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100454</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Drugs: cardiovascular system, Stroke, Ethics]]></dc:subject>
<dc:title><![CDATA[Of people admitted within 2 h of mild/improving stroke, 31% do not receive rtPA, although many of these people have poor outcomes]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Prognosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100343v1?rss=1">
<title><![CDATA[For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100343v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Atrial fibrillation (AF) significantly increases the risk of thromboembolism. Until recently, thromboprophylaxis in high-risk AF patients has been limited to vitamin K antagonists. Emerging, novel oral anticoagulants are more selective, targeting specific steps in the coagulation cascade. These agents include direct thrombin inhibitors such as dabigatran and Factor Xa inhibitors such as rivaroxaban, and apixaban. These medications bring the potential for decreased monitoring and improved risk profiles with regard to bleeding and drug-drug interactions.</p></sec><sec id="s2"><st>Methods</st><p>Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) was an international, multicentre, event-driven non-inferiority trial comparing rivaroxaban versus dose-adjusted warfarin for the prevention of stroke and systemic embolism (primary efficacy endpoint). ROCKET AF enrolled 14264 patients with non-valvular AF at moderate to high risk of stroke and randomised them in a double-blind, double-dummy fashion, administering placebo pills and...]]></description>
<dc:creator><![CDATA[Sherwood, M., Piccini, J. P.]]></dc:creator>
<dc:date>2012-02-18T02:03:24-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100343</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100343</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Drugs: cardiovascular system, Stroke, Arrhythmias]]></dc:subject>
<dc:title><![CDATA[For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100383v1?rss=1">
<title><![CDATA[Robustness, risk and responsivity in early language acquisition: a randomised trial of a low-intensity language promotion programme for slow to talk toddlers finds no effects on language or behavioural development]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100383v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Language is a robust developmental phenomenon, characterised by rapid and prodigious growth and change in the first 3 years of life. It is a universal capability that is acquired effortlessly by most children. Adult input is essential to acquiring language so that children learn the languages spoken to them. Predictable milestones observed in early language development are the onset of first words followed by combining single words in simple sentences. Across cultures, child rearing practices and childhood experiences suggest that powerful neurodevelopmental mechanisms guide the onset and timing of these milestones.</p><p>An important counterfactual observation is that language acquisition is not robust for all children. An estimated 7% of 5-year-old children have specific language impairment (SLI).<cross-ref type="bib" refid="R1">1</cross-ref> Children with SLI do not achieve language milestones as expected. For these otherwise healthy children, late onset of first words, small expressive vocabulary size and persistence of single words beyond 24 months...]]></description>
<dc:creator><![CDATA[Taylor, C. L.]]></dc:creator>
<dc:date>2012-02-18T02:03:24-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100383</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100383</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies]]></dc:subject>
<dc:title><![CDATA[Robustness, risk and responsivity in early language acquisition: a randomised trial of a low-intensity language promotion programme for slow to talk toddlers finds no effects on language or behavioural development]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100412v1?rss=1">
<title><![CDATA[Gender-based violence, perinatal mental health in women and child development]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100412v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Interpersonal violence is regarded as a global public health problem by the WHO,<cross-ref type="bib" refid="R1">1</cross-ref> whose definition includes that it is intentional, a misuse of power and results in psychological harm. The United Nations Declaration on the Elimination of Violence against Women<cross-ref type="bib" refid="R2">2</cross-ref> defines any act of violence against women in their families, the general community or that perpetrated by the state as gender-based violence. It acknowledges that women are more vulnerable than men to all forms of violence, which is a very well-established risk factor for depression, post-traumatic stress disorder and suicidal behaviours.<cross-ref type="bib" refid="R3">3</cross-ref></p><p>Recent evidence about the effect of antenatal anxiety in women on the development of subsequent emotional and behavioural problems in their children, while important in identifying need for effective early interventions, has paid less attention to causes. Home is optimally a haven, in which there is physical and psychological safety. The possibility that...]]></description>
<dc:creator><![CDATA[Fisher, J.]]></dc:creator>
<dc:date>2012-02-18T02:03:24-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100412</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100412</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Pregnancy, Developmental paediatrics, Anxiety disorders (including OCD and PTSD), Child and adolescent psychiatry, Mood disorders (including depression)]]></dc:subject>
<dc:title><![CDATA[Gender-based violence, perinatal mental health in women and child development]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100065v1?rss=1">
<title><![CDATA[Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100065v1?rss=1</link>
<description><![CDATA[<sec><st>Context</st><p>The need for comparative effectiveness (CE) data continues to grow, fuelled by market demand as well as health reform. There may be an assumption that new drugs result in improved efficacy compared with the standard of care, therefore warranting premium prices. Gout treatment has recently become controversial, as expensive new drugs enter the market with limited CE data.</p></sec><sec><st>Methods</st><p>The authors reviewed published clinical trials and conducted a cost effectiveness analysis on a new drug (febuxostat) versus the standard (allopurinol) to illustrate the limitations in using these data to inform evidence-based decision-making.</p></sec><sec><st>Findings</st><p>Although febuxostat trials included allopurinol as a comparator, methodological limitations make comparative effectiveness evaluations difficult. However, when available trial data were input to a decision analytic model, the authors found that a significant reduction in febuxostat cost would be required in order for it to dominate allopurinol in cost effectiveness analysis. This case exemplifies the challenges of using clinical trial data in comparative and cost effectiveness analyses.</p></sec>]]></description>
<dc:creator><![CDATA[Meltzer, M., Pizzi, L. T., Jutkowitz, E.]]></dc:creator>
<dc:date>2012-02-18T02:03:24-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100065</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100065</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Health policy, Genetics, Degenerative joint disease, Musculoskeletal syndromes, Health economics, Health service research]]></dc:subject>
<dc:title><![CDATA[Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Perspective</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100489v1?rss=1">
<title><![CDATA[Lung cancer screening with chest radiography has no effect on lung cancer incidence or mortality]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100489v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>In the 1970s and 1980s, randomised controlled trials of lung cancer screening with chest radiography and sputum cytology found no lung cancer mortality reduction among high-risk patients.<cross-ref type="bib" refid="R1">1</cross-ref> Evidence-based guidelines have since recommended against lung cancer screening, although many physicians still endorse screening for high-risk patients, such as chronic smokers.<cross-ref type="bib" refid="R2">2</cross-ref></p><p>The Mayo Lung Study, for example, compared screening with chest radiography and sputum cytology every 4 months to no screening among male, chronically heavy smokers over a 6-year period. Although screening was associated with higher incidence of lung cancer, no benefits in lung cancer mortality were observed, and the extra incidence was most likely attributable to overdiagnosis.</p><p>Early trials, however, may have been underpowered, and modern radiography may be more sensitive for resectable lung cancers. The National Lung Screening Trial (NLST) recently reported a 20% lung cancer mortality reduction among high-risk patients receiving annual low-dose CT screening compared...]]></description>
<dc:creator><![CDATA[Fenton, J. J.]]></dc:creator>
<dc:date>2012-02-18T02:03:24-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100489</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100489</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Smoking and tobacco, Clinical trials (epidemiology), Epidemiologic studies, Screening (oncology), Radiology, Clinical diagnostic tests, Radiology (diagnostics), Prostate, Screening (epidemiology), Guidelines, Health education, Screening (public health), Smoking]]></dc:subject>
<dc:title><![CDATA[Lung cancer screening with chest radiography has no effect on lung cancer incidence or mortality]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100337v1?rss=1">
<title><![CDATA[Breast feeding is associated with decreased risk of sudden infant death syndrome]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100337v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Studies have been inconsistent in showing a protective effect of breast feeding on the risk of sudden infant death syndrome (SIDS). Therefore, the meta-analysis by Hauck <I>et al</I> is timely as it aims to quantify and evaluate the protective effect of breast feeding against SIDS, and provide recommendations on the utility of breast feeding as a strategy for reducing the risk of SIDS.</p></sec><sec id="s2"><st>Methods</st><p>Data on breast feeding and its association with SIDS published from January 1966 to December 2009 were collected from the MEDLINE database. Twenty-four original case-control studies that provided data on the relationship between breast feeding and SIDS risk were identified. Two teams of two reviewers independently evaluated the studies.</p><p>The authors analysed the following; (1) breast feeding of any amount (partial or exclusive) or duration, including breast feeding at discharge from the hospital, (2) breast feeding of any amount at the age of 2 months or older...]]></description>
<dc:creator><![CDATA[Zotter, H., Pichler, G.]]></dc:creator>
<dc:date>2012-02-18T02:03:24-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100337</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100337</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Childhood nutrition]]></dc:subject>
<dc:title><![CDATA[Breast feeding is associated with decreased risk of sudden infant death syndrome]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100227v1?rss=1">
<title><![CDATA[How much doctoral research on clinical topics is published?]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100227v1?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To determine how often clinical research from doctoral degree programmes is unpublished and to see if one can characterise differences between those researchers who do or do not publish their work or between the institutions where they studied.</p></sec><sec><st>Design</st><p>Secondary research with data in the public domain: combining a national dataset of healthcare doctoral theses with related publications traceable in two widely accessible databases.</p></sec><sec><st>Data sources</st><p>The Index to Theses was searched for UK doctoral theses and the databases Web of Knowledge and SCOPUS searched by author name for literature derived from each thesis. Confirmatory details about student names or their doctoral programmes were obtained from university websites, if required.</p></sec><sec><st>Eligibility criteria</st><p>Search terms were chosen to identify only projects directly related to human health. Thesis records included &lsquo;clinical trials&rsquo; or &lsquo;clinical research&rsquo;. The awards were all doctorate-level degrees between 2000 and 2010. &lsquo;Related&rsquo; publication in the Web of Knowledge or SCOPUS was interpreted very broadly to include publications with any research commonality with the degree project as recorded in the Index to Theses.</p></sec><sec><st>Results</st><p>A sample of 82 theses from 39 universities provided the initial material for a literature search. The Web of Knowledge contained more publications from more students than SCOPUS held. Of the doctoral research samples, 39 out of 82 theses (47.6%) produced no discernable publications. The 43 students whose research was published typically began publishing before completing their degree (mean time 1.3 years preceding their award). Not all types of doctorates were associated equally with publication: all 11 MD theses in our sample had related publications (100%).</p></sec><sec><st>Conclusions</st><p>Research evidence associated with doctoral degrees is often left unpublished, across many settings. Sharing such evidence is a scientific and ethical duty. Supporting students in publishing preliminary work while they are still in doctoral programmes may be the most productive response. The large number of doctorates awarded in &lsquo;medical&rsquo; disciplines every year represents a substantial investment in training and a resource for evidence-based medicine that should not be squandered.</p></sec>]]></description>
<dc:creator><![CDATA[Caan, W., Cole, M.]]></dc:creator>
<dc:date>2012-02-18T02:03:23-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100227</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100227</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:title><![CDATA[How much doctoral research on clinical topics is published?]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Original EBM research</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100358v1?rss=1">
<title><![CDATA[Exposure to trimethoprim-sulfamethoxazole is associated with hospitalisation for hyperkalaemia in older people treated with spironolactone]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100358v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Trimethoprim&ndash;sulfamethoxazole (TMP&ndash;SMX) is a combination antibiotic used for a number of infectious diseases and organisms.<cross-ref type="bib" refid="R1">1</cross-ref> It is generally well tolerated; however, electrolyte disturbances, primarily hyperkalaemia, have been reported with both standard and high-dose therapy.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> Spironolactone, an aldosterone receptor antagonist, predominantly used in the management of heart failure and cirrhosis, is also known to cause hyperkalaemia.<cross-ref type="bib" refid="R3">3</cross-ref> The risk of developing hyperkalaemia during co-administration of these two commonly prescribed medications is unknown. Antoniou <I>et al</I> describe the association between hospitalisation for hyperkalaemia and prior use of TMP&ndash;SMX in an older population receiving spironolactone.</p></sec><sec id="s2"><st>Methods</st><p>The authors completed a population-based, nested case-control study with the objective of characterising the association between hospitalisation for hyperkalaemia and TMP&ndash;SMX use in an older population treated with spironolactone. Older subjects aged 66 years or greater, treated with spironolactone, were potentially eligible for inclusion. Within a group of continuous...]]></description>
<dc:creator><![CDATA[Dunn, R. L.]]></dc:creator>
<dc:date>2012-02-18T02:03:23-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100358</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100358</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Geriatric medicine, Epidemiologic studies, Urinary tract infections, Renal medicine, Vulvovaginal disorders, Urinary tract infections]]></dc:subject>
<dc:title><![CDATA[Exposure to trimethoprim-sulfamethoxazole is associated with hospitalisation for hyperkalaemia in older people treated with spironolactone]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100479v1?rss=1">
<title><![CDATA[Failure to detect a link between mobile phone use and brain tumours in a large Danish cohort study: but findings may be due to bias]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100479v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>After the introduction of digital mobile phone systems in the 1990s, a growing number of people were using these devices that raised concerns about possible health consequences because even small risks could be of public health relevance if the number of exposed were large. A surge of controversy about possible health effects of radio frequency electromagnetic fields occurred and, although the majority of scientists maintained the view that mobile phone use was safe, possible health effects began to be studied in epidemiological, animal experimental and in vitro investigations. In this context the Danish cohort study was initiated in the mid-1990s.</p></sec><sec id="s2"><st>Methods</st><p>The original study was a retrospective cohort study with 420 095 subscribers selected from 723 421 records from mobile phone companies from 1982 to 1995. A total of 200 507 corporate subscribers were excluded. The present study by Frei <I>et al</I> included only subscribers who were present in a...]]></description>
<dc:creator><![CDATA[Kundi, M.]]></dc:creator>
<dc:date>2012-02-18T02:03:23-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100479</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100479</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies]]></dc:subject>
<dc:title><![CDATA[Failure to detect a link between mobile phone use and brain tumours in a large Danish cohort study: but findings may be due to bias]]></dc:title>
<prism:publicationDate>2012-02-18</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100472v1?rss=1">
<title><![CDATA[Vitamin E and selenium do not decrease prostate cancer incidence: vitamin E may actually increase it]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100472v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>The Selenium and vitamin E Cancer Prevention Trial (SELECT)<cross-ref type="bib" refid="R1">1</cross-ref> trial was designed to determine whether oral selenium, vitamin E or both could affect a man's risk of being diagnosed with prostate cancer. Interim analysis of the trial had shown no benefit to supplementation with selenium and vitamin E on the incidence of prostate cancer. The study by Klein <I>et al</I> presents updated results from a longer follow-up period.</p></sec><sec id="s2"><st>Methods</st><p>The effect of selenium and vitamin E on the risk of prostate cancer was studied in 35 151 study subjects. Men were eligible if they were at least 55 years old (50 years old for African&ndash;American men), had a normal digital rectal exam (DRE), prostate specific antigen (PSA) &lt;4 ng/ml and no history of prostate cancer. Men were randomly and equally distributed in a double blinded fashion among the four study groups: selenium daily, vitamin E daily, selenium plus...]]></description>
<dc:creator><![CDATA[Jain, S., Munver, R., Sawczuk, I. S.]]></dc:creator>
<dc:date>2012-02-03T00:05:02-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100472</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100472</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Smoking and tobacco, Clinical trials (epidemiology), Prevention, Screening (oncology), Radiology, Surgical diagnostic tests, Clinical diagnostic tests, Prostate, Screening (epidemiology), Health education, Screening (public health), Smoking]]></dc:subject>
<dc:title><![CDATA[Vitamin E and selenium do not decrease prostate cancer incidence: vitamin E may actually increase it]]></dc:title>
<prism:publicationDate>2012-02-03</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100471v1?rss=1">
<title><![CDATA[Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100471v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Lipids are typically measured after an 8&ndash;12 h fast. Most patients are not fasting when they are initially evaluated by their providers, meaning that a repeat visit is necessary if a fasting blood draw is required. However, if postprandial effects do not substantially alter lipid levels, then a non-fasting blood draw has many practical advantages for clinical practice, particularly in paediatrics where fasting is a challenge. Recent studies in adults have suggested that non-fasting lipids may suffice for initial screening of cardiovascular risk,<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3"></cross-ref><cross-ref type="bib" refid="R4"></cross-ref><cross-ref type="bib" refid="R5">5</cross-ref> but data in children are scarce. Therefore, the investigators conducted a large cross-sectional study in children to assess differences in lipid values based on fasting status.</p></sec><sec id="s2"><st>Methods</st><p>The study participants were 12 744 children aged 3&ndash;17 (mean=11) years from the National Health and Nutrition Examination Surveys (1999&ndash;2008). Information on time since last food or drink was available...]]></description>
<dc:creator><![CDATA[Mora, S.]]></dc:creator>
<dc:date>2012-01-31T04:37:13-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100471</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100471</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Drugs: cardiovascular system, Childhood nutrition, Diet, Screening (epidemiology), Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels]]></dc:title>
<prism:publicationDate>2012-01-31</prism:publicationDate>
<prism:section>Diagnosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100422v1?rss=1">
<title><![CDATA[Patients on three times-weekly haemodialysis have increased mortality during the long, 2-day interdialytic interval]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100422v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>People on long-term haemodialysis are dialysed three times-weekly such as on Mondays, Wednesdays and Fridays. Accumulation of volume and toxins over the longer 2-day interdialytic interval (eg, Friday&ndash;Monday) may provoke excess deaths. The cohort study by Foley <I>et al</I> asked the question whether compared with other days, morbidity and mortality is increased during the long interdialytic interval.</p></sec><sec id="s2"><st>Methods</st><p>The participants were 32 065 adults in the USA who participated in the End-Stage Renal Disease (ESRD) Clinical Performance Measures Project at the end of calendar years 2004 through 2007. Patients were excluded if they were not receiving haemodialysis three times weekly. The outcomes were various causes of morbidity and mortality and their relationship with the day of dialysis. The mean follow-up was 2.2 years. Existing United States Renal Data System Standard Analytical Files were used to determine dates of hospitalisations, deaths and their causes. Poisson regression was used to calculate event...]]></description>
<dc:creator><![CDATA[Agarwal, R.]]></dc:creator>
<dc:date>2012-01-31T04:37:13-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100422</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100422</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Drugs: gastrointestinal system, Epidemiologic studies, Immunology (including allergy), Drugs: cardiovascular system, Heart failure, Stroke, Hypertension, Interventional cardiology, Ischaemic heart disease, Renal medicine, Arrhythmias]]></dc:subject>
<dc:title><![CDATA[Patients on three times-weekly haemodialysis have increased mortality during the long, 2-day interdialytic interval]]></dc:title>
<prism:publicationDate>2012-01-31</prism:publicationDate>
<prism:section>Prognosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100477v1?rss=1">
<title><![CDATA[Early introduction of allergenic food is not associated with increased report of wheeze or eczema]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100477v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Previously, many non-evidence-based recommendations have been made regarding delayed introduction of so-called allergenic foods such as cow's milk protein, eggs, peanuts, tree nuts, soy and gluten. Tromp <I>et al</I> examined whether the timing of introduction of these foods in infancy is associated with eczema and wheezing in children 4 years of age or younger in a comprehensive population-based prospective cohort study of newborns followed up to 4 years of age.<cross-ref type="bib" refid="R1">1</cross-ref></p><p>Recently, the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) published a commentary on complementary feeding that recommends delaying introduction of solid foods until the child is 4&ndash;6 months of age; the introduction of complementary food should not be delayed beyond the age of 61/2 months based on the results from recent birth cohort studies.<cross-ref type="bib" refid="R1">1</cross-ref> These recommendations are in line with previous recommendations published in 2004 by an expert group set up by the Section...]]></description>
<dc:creator><![CDATA[Host, A.]]></dc:creator>
<dc:date>2012-01-31T04:37:13-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100477</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100477</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Immunology (including allergy), Childhood nutrition, Diet, Asthma, Dermatology, Clinical diagnostic tests, Ear, nose and throat/otolaryngology]]></dc:subject>
<dc:title><![CDATA[Early introduction of allergenic food is not associated with increased report of wheeze or eczema]]></dc:title>
<prism:publicationDate>2012-01-31</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100478v1?rss=1">
<title><![CDATA[Overweight and obese individuals following either commercial or primary care-led weight loss programmes achieve significant weight loss at the end of the 12-week programme, but only the commercial programmes studied had sustained effect to 1 year]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100478v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Overweight and obesity is one of the most important public health issues in many parts of the world today. As reported by Jolly <I>et al</I>, the WHO has referred to the current situation as a global epidemic. Others have suggested that the rise in levels of obesity will cause a decline in life expectancy in the USA in the 21st century.<cross-ref type="bib" refid="R1">1</cross-ref> Achieving and maintaining weight loss is not easy either for the individual attempting the weight loss or the provider of advice, guidance or support. The present randomised trial compares a number of different approaches to weight management with adequate statistical power to deliver meaningful outcome comparisons.</p></sec><sec id="s2"><st>Methods</st><p>The investigators evaluated eight weight loss programmes. Three programmes were commercially provided (ie, Weight Watchers, Slimming World and Rosemary Conley) though participants paid with vouchers provided by investigators, two were &lsquo;one to one&rsquo; counselling (General Practice led or Pharmacy led)...]]></description>
<dc:creator><![CDATA[Davies, P. S. W.]]></dc:creator>
<dc:date>2012-01-31T04:37:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100478</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100478</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), General practice / family medicine, Obesity (nutrition), Health education]]></dc:subject>
<dc:title><![CDATA[Overweight and obese individuals following either commercial or primary care-led weight loss programmes achieve significant weight loss at the end of the 12-week programme, but only the commercial programmes studied had sustained effect to 1 year]]></dc:title>
<prism:publicationDate>2012-01-31</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100469v1?rss=1">
<title><![CDATA[Telaprevir triple combination therapy, and dual peginterferon {alpha}-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naive patients with genotype 1 hepatitis C virus infection]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100469v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Until recently, the standard of care for hepatitis C virus (HCV) infection has been pegylated interferon and ribavirin for 48 weeks for genotype 1 and 24 weeks for genotype 3 infection, with overall sustained virological response (SVR), which equates to cure, of 50% and 80%, respectively. With the recent licensing of the protease inhibitors telaprevir and boceprevir, first generation direct acting antivirals (DAAs), we are at the dawn of a new era of HCV therapy. The ILLUMINATE study explores response-guided therapy in HCV treatment na&iuml;ve individuals using telaprevir in combination with pegylated interferon and ribavirin.</p></sec><sec id="s2"><st>Methods</st><p>ILLUMINATE is a phase 3 non-inferiority study exploring shorter course therapy for HCV infection using triple therapy with telaprevir 750 mg orally every 8 h, pegylated interferon &alpha;-2a 180 mcg subcutaneously weekly and ribavirin 1000&ndash;1200 mg daily. All patients were treated with telaprevir for 12 weeks and at least 24 weeks of pegylated interferon...]]></description>
<dc:creator><![CDATA[Danta, M.]]></dc:creator>
<dc:date>2012-01-31T04:37:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100469</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100469</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Liver disease, Immunology (including allergy), Hepatitis and other GI infections, Hepatitis (sexual health)]]></dc:subject>
<dc:title><![CDATA[Telaprevir triple combination therapy, and dual peginterferon {alpha}-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naive patients with genotype 1 hepatitis C virus infection]]></dc:title>
<prism:publicationDate>2012-01-31</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100473v1?rss=1">
<title><![CDATA[Physical education combined with pedometer use is associated with better glucose tolerance among overweight/obese with impaired glucose tolerance; no benefit for education alone]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100473v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Type 2 diabetes is a preventable disease. As with cervical cancer and colon cancer, every new case of type 2 diabetes is evidence of a failure of our public health and medical care systems to address and mitigate the risk factors for this common and costly chronic illness.</p><p>The Diabetes Prevention Program (DPP) study demonstrated that in high-risk individuals, a lifestyle intervention targeting modest weight loss, a healthy lower fat diet and physical activity equivalent to about 30 min of walking a day can reduce the RR of developing type 2 diabetes by 58%.<cross-ref type="bib" refid="R1">1</cross-ref> However, the actual intervention in the DPP was expensive and included intensive one-on-one lifestyle coaching. Since the publication of the DPP results in 2002, investigators have been working to find a less expensive and more easily disseminated way to deliver the DPP lifestyle intervention. The Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement...]]></description>
<dc:creator><![CDATA[Richardson, C. R.]]></dc:creator>
<dc:date>2012-01-31T04:37:12-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100473</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100473</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Diet, Obesity (nutrition), Screening (oncology), Vulvovaginal disorders, Screening (epidemiology), Diabetes, Health education, Screening (public health)]]></dc:subject>
<dc:title><![CDATA[Physical education combined with pedometer use is associated with better glucose tolerance among overweight/obese with impaired glucose tolerance; no benefit for education alone]]></dc:title>
<prism:publicationDate>2012-01-31</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100381v1?rss=1">
<title><![CDATA[Cardiovascular risks of stopping antiplatelet therapy before non-cardiac surgery for patients with coronary stents]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100381v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>The use of stents in percutaneous coronary intervention (PCI) increases procedural success and decreases restenosis, but it complicates subsequent surgical procedures in these patients.<cross-ref type="bib" refid="R1">1</cross-ref> Between 5% and 15% of PCI patients undergo non-cardiac surgery in the year following PCI, and are at high risk of experiencing cardiovascular (CV) complications.<cross-ref type="bib" refid="R2">2</cross-ref> The most serious risk is stent thrombosis, which occurs in 2.5% of patients and is fatal in 40%.<cross-ref type="bib" refid="R3">3</cross-ref> Although guidelines for the management of these patients are available, the evidence supporting them is lacking.<cross-ref type="bib" refid="R4">4</cross-ref> Key questions remain regarding contemporary rates and timing of surgery after PCI, risks of both CV and haemorrhagic complications during the peri-operative period and the management and impact of antiplatelet therapies for these patients.</p></sec><sec id="s2"><st>Methods</st><p>Albaladejo <I>et al</I> studied 1134 consecutively enrolled French patients with coronary stents who underwent subsequent surgical procedures. Patients were enrolled from 47 different centres...]]></description>
<dc:creator><![CDATA[Maddox, T. M.]]></dc:creator>
<dc:date>2012-01-31T04:37:13-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100381</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100381</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Stroke, Interventional cardiology, Venous thromboembolism, Radiology, Renal medicine, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Cardiovascular risks of stopping antiplatelet therapy before non-cardiac surgery for patients with coronary stents]]></dc:title>
<prism:publicationDate>2012-01-31</prism:publicationDate>
<prism:section>Prognosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100334v1?rss=1">
<title><![CDATA[The use of 50% nitrous oxide improves successful intravenous access in obese and growth-limited children in an outpatient setting]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100334v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Intravenous therapy is a common intervention in paediatric medicine. Its uses include the delivery of fluids, nutrition, medication and venous blood sampling. Patient anxiety and difficulty with intravenous placement are common. Patients who require frequent peripheral intravenous placement can have progressive difficulty with intravenous access and can also experience increased anxiety related to the procedure. Obesity or growth retardation can make intravenous insertion more difficult.</p><p>Topical anaesthetic applied to the skin over an intravenous insertion site has been shown to decrease pain and anxiety related to the procedure.<cross-ref type="bib" refid="R1">1</cross-ref> Oral midazolam and inhaled nitrous oxide are well studied common pharmacologic therapies noted to relieve anxiety and facilitate cooperation with procedures in children,<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> but their role in improving successful intravenous access in children has not previously been evaluated.</p></sec><sec id="s2"><st>Methods</st><p>A total of 90 children were studied prospectively. Of these, 60 were obese and 30 were growth...]]></description>
<dc:creator><![CDATA[Rosen, D.]]></dc:creator>
<dc:date>2012-01-19T00:41:08-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100334</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100334</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Palliative care, Patients, Pain (neurology), Stroke, Childhood nutrition, Obesity (nutrition), Interventional cardiology, Radiology, Clinical diagnostic tests, Health education]]></dc:subject>
<dc:title><![CDATA[The use of 50% nitrous oxide improves successful intravenous access in obese and growth-limited children in an outpatient setting]]></dc:title>
<prism:publicationDate>2012-01-19</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100361v1?rss=1">
<title><![CDATA[Preterm birth, a known risk factor for infant and childhood death, is an independent risk factor for mortality in early childhood and young adulthood]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100361v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Preterm birth, delivery before 37 weeks gestation, is a leading cause of perinatal morbidity and mortality worldwide.<cross-ref type="bib" refid="R1">1</cross-ref> Despite extensive research efforts, the prevalence of preterm birth in the USA has increased to 12% over the last 30 years compared with 5&ndash;9% in Europe.<cross-ref type="bib" refid="R2">2</cross-ref> Furthermore, pharmacologic and medical technologic advances (eg, antenatal corticosteroids, antibiotic prophylaxis, surfactant therapy and high-frequency ventilation) have led to significantly improved survival among preterm-born individuals.<cross-ref type="bib" refid="R3">3</cross-ref> Although much is known about the short-term effect of preterm birth,<cross-ref type="bib" refid="R4">4</cross-ref> less is known about longer-term outcomes in adulthood. Given the increasing preterm birth survivorship and the inability, thus far, to significantly reduce preterm birth, understanding its effect on adult health is of particular public health relevance.</p></sec><sec id="s2"><st>Methods</st><p>In order to examine the association between gestational age and mortality in young adulthood, Crump <I>et al</I> used the Swedish Birth Registry to analyse singleton infants...]]></description>
<dc:creator><![CDATA[Swamy, G. K.]]></dc:creator>
<dc:date>2011-12-22T01:27:00-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100361</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100361</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Pregnancy]]></dc:subject>
<dc:title><![CDATA[Preterm birth, a known risk factor for infant and childhood death, is an independent risk factor for mortality in early childhood and young adulthood]]></dc:title>
<prism:publicationDate>2011-12-22</prism:publicationDate>
<prism:section>Prognosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100332v1?rss=1">
<title><![CDATA[Some oral antidiabetic medications may prevent type 2 diabetes in people at high risk for it, but the evidence is insufficient to determine whether the potential benefits outweigh the possible risks]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100332v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Type 2 diabetes has its origins in obesity-associated insulin resistance compounded by a progressive inability to secrete adequate amounts of insulin in compensation. Clinical trials have shown that non-pharmacological strategies can reduce the risk of progression of glucose intolerance to diabetes in obese glucose-intolerant individuals. All too often however, clinical practice exposes the difficulties that many people have in achieving and sustaining lifestyle changes. Alternative strategies for diabetes prevention have therefore been sought.</p></sec><sec id="s2"><st>Methods</st><p>In this meta-analysis, Phung <I>et al</I> identified randomised controlled studies (placebo or active comparator) of at least 3 months duration that each enrolled at least 20 participants. In addition to a conventional meta-analysis, the authors performed a mixed-treatment comparison. The aim of the latter analysis was to determine the comparative efficacy of three classes of oral glucose-lowering drugs via indirect between-trial comparisons. A number of prespecified subgroup sensitivity analyses were also performed. The study was funded...]]></description>
<dc:creator><![CDATA[Krentz, A. J.]]></dc:creator>
<dc:date>2011-12-22T01:27:00-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100332</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100332</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Health policy, Genetics, Drugs: cardiovascular system, Obesity (nutrition), Musculoskeletal syndromes, Health economics, Health service research, Diabetes, Health education]]></dc:subject>
<dc:title><![CDATA[Some oral antidiabetic medications may prevent type 2 diabetes in people at high risk for it, but the evidence is insufficient to determine whether the potential benefits outweigh the possible risks]]></dc:title>
<prism:publicationDate>2011-12-22</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100355v1?rss=1">
<title><![CDATA[Oral ondansetron decreases vomiting, as well as the need for intravenous fluids and hospital admission, in children with acute gastroenteritis]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100355v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Antiemetic use is common in children. The majority of paediatric practitioners prescribe antiemetics for intractable vomiting due to gastroenteritis.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> Though gastroenteritis is self-limited, vomiting is unpleasant and may lead to dehydration and hospitalisation. The review by Fedorowicz <I>et al</I> evaluated the clinical effects and adverse events of antiemetics in the setting of gastroenteritis.</p></sec><sec id="s2"><st>Methods</st><p>This is an update of a review done initially in 2005, 2006 and 2008. The review includes randomised controlled studies of children aged less than 18 years, who received antiemetics orally, intravenously or rectally for vomiting as a result of gastroenteritis. The primary outcome of the review was the time from first administration of the treatment until cessation of vomiting. The secondary outcomes were parenteral satisfaction, number of patients requiring hospitalisation or intravenous rehydration during an emergency department (ED) stay and up to 72 h after discharge, mean number of episodes...]]></description>
<dc:creator><![CDATA[Levine, D. A.]]></dc:creator>
<dc:date>2011-12-22T01:27:01-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100355</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100355</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Drugs: gastrointestinal system, Infection (gastroenterology), Neurogastroenterology, Drugs: musculoskeletal and joint diseases]]></dc:subject>
<dc:title><![CDATA[Oral ondansetron decreases vomiting, as well as the need for intravenous fluids and hospital admission, in children with acute gastroenteritis]]></dc:title>
<prism:publicationDate>2011-12-22</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100345v1?rss=1">
<title><![CDATA[Evening dosing of antihypertensive medications results in better blood pressure control and decreases cardiovascular morbidity and mortality in patients with Type 2 diabetes]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100345v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Although Systolic Hypertension in Europe<cross-ref type="bib" refid="R1">1</cross-ref> and Heart Outcomes Prevention Evaluation<cross-ref type="bib" refid="R2">2</cross-ref> studies suggested nightly dosing of antihypertensive medications might lead to better cardiovascular outcomes, the Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular trial (ABPM),<cross-ref type="bib" refid="R3">3</cross-ref> or Monitorizaci&oacute;n Ambulatoria para Predicci&oacute;n de Eventos Cardiovasculares (MAPEC), was the first study to include a comparison group randomised to morning only therapy. MAPEC showed improved blood pressure (BP) control, increased prevalence of normal sleep time blood pressure decline (ie, dipping) and reduced cardiovascular morbidity and mortality with nighttime chronotherapy. Since people with diabetes are prone to nocturnal hypertension, Hermida <I>et al</I> examine how this beneficial effect is modulated in a subset of patients from the MAPEC trial with diabetes and hypertension.</p></sec><sec id="s2"><st>Methods</st><p>In an open-label study, 448 patients from a single centre with Type 2 diabetes and hypertension were randomised to receive all antihypertensive medications in the morning (control...]]></description>
<dc:creator><![CDATA[Mohandas, R., Ejaz, A. A.]]></dc:creator>
<dc:date>2011-12-22T01:27:01-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100345</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100345</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Genetics, Drugs: cardiovascular system, Stroke, Hypertension, Ischaemic heart disease, Diabetes]]></dc:subject>
<dc:title><![CDATA[Evening dosing of antihypertensive medications results in better blood pressure control and decreases cardiovascular morbidity and mortality in patients with Type 2 diabetes]]></dc:title>
<prism:publicationDate>2011-12-22</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100353v1?rss=1">
<title><![CDATA[Positive parenting in adolescence is associated with well-(adaptive-) functioning adult offspring]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100353v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Parenting behaviours clearly have an effect on children but how they impact adult behaviour has received less attention. Johnson <I>et al</I> aimed to determine the association between parenting behaviours and the coping skills, interpersonal skills and personality traits of children that persist into adulthood. They examined this issue by conducting longitudinal research with mothers and children. Prior meta-analyses show positive parenting programmes work for improving children's behaviours.<cross-ref type="bib" refid="R1">1</cross-ref> This study provides additional evidence of a long-term effect.</p></sec><sec id="s2"><st>Methods</st><p>Mothers and offspring of the 669 families who participated reported on positive parenting (eg, affection, praise and communication) and child behaviours when the offspring were around 16 years of age. At follow-up, adaptive functioning (eg, optimism, insight/warmth, productivity and being assertive or expressing oneself skilfully) and personality disorder symptoms were measured. Mothers reported on their own and the father's psychiatric symptoms. Mothers and offspring reported on the father's parenting. While 10...]]></description>
<dc:creator><![CDATA[Munoz, L. C.]]></dc:creator>
<dc:date>2011-12-22T01:27:00-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100353</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100353</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Child and adolescent psychiatry, Personality disorders]]></dc:subject>
<dc:title><![CDATA[Positive parenting in adolescence is associated with well-(adaptive-) functioning adult offspring]]></dc:title>
<prism:publicationDate>2011-12-22</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100318v1?rss=1">
<title><![CDATA[Caudal epidural steroid injections no better than saline epidurals or sham injections for the treatment of chronic lumbar radiculopathy]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100318v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Epidural steroid injections are commonly used for the treatment of lumbar radiculopathies which have failed other conservative measures such as physical therapy or non-steroidal anti-inflammatories. Although the use of such injections has risen considerably over recent years, their efficacy remains unclear. This randomised trial compared disability following epidural steroids, epidural saline or sham injections.</p></sec><sec id="s2"><st>Methods</st><p>Of 461 patients presenting with chronic radiculopathy (duration &gt;12 weeks), 116 patients met the inclusion criteria and were enrolled in the study. Among several exclusion criteria were patients with secondary gain issues who would be unlikely to respond favourably, prior surgery, pregnancy, deformity, morbid obesity, cauda equina syndrome, severe weakness and severe pain (referred for surgery).</p><p>Two control groups were used, one of which received a sham subcutaneous injection (n=40) and another that underwent epidural saline injection (n=39). The treatment group underwent caudal epidural injection of saline plus 40 mg triamcinolone (n=37). The primary outcome measure...]]></description>
<dc:creator><![CDATA[Weiner, B. K., Fernandez-Moure, J.]]></dc:creator>
<dc:date>2011-12-20T02:04:09-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100318</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100318</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Rehabilitation medicine, Clinical trials (epidemiology), Neuromuscular disease, Pain (neurology), Peripheral nerve disease, Obesity (nutrition), Pregnancy, Drugs: musculoskeletal and joint diseases, Sports and exercise medicine, Health education]]></dc:subject>
<dc:title><![CDATA[Caudal epidural steroid injections no better than saline epidurals or sham injections for the treatment of chronic lumbar radiculopathy]]></dc:title>
<prism:publicationDate>2011-12-20</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100378v1?rss=1">
<title><![CDATA[Breastfeeding by mothers infected with hepatitis B carries no increased risk of transmission to infants who receive proper immunoprophylaxis: a meta-analysis]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100378v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Hepatitis B (HBV) remains a global health concern with 350 million people chronically infected, and transmission still occurs despite the widely available and efficacious vaccine. Mother-to-child transmission (MTCT) is an ongoing problem in many countries, and in countries with high prevalence of HBV (&gt;8%), only 44% have birth dose vaccine implemented into the infant vaccine schedule.<cross-ref type="bib" refid="R1">1</cross-ref> Currently, the Centers for Disease Control and Prevention recommends the use of hepatitis B immune globulin (HBIG) and HBV vaccine given at the time of birth with two additional doses of the vaccine in the first 6 months of life to prevent perinatal transmission.<cross-ref type="bib" refid="R2">2</cross-ref> With the successful implementation of this immunoprophylaxis strategy, MTCT of HBV has been reduced to less than 10%, with highest risk being in mothers with high viraemia.<cross-ref type="bib" refid="R3">3</cross-ref></p><p>Breastfeeding the newborn of an infected HBV mother has been controversial as it has been shown that...]]></description>
<dc:creator><![CDATA[Tran, T. T.]]></dc:creator>
<dc:date>2011-12-20T02:04:09-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100378</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100378</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Liver disease, Journalology, Immunology (including allergy), Hepatitis and other GI infections, Vaccination / immunisation, Childhood nutrition, Pregnancy, Hepatitis (sexual health)]]></dc:subject>
<dc:title><![CDATA[Breastfeeding by mothers infected with hepatitis B carries no increased risk of transmission to infants who receive proper immunoprophylaxis: a meta-analysis]]></dc:title>
<prism:publicationDate>2011-12-20</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100147v1?rss=1">
<title><![CDATA[Varenicline for 4 weeks prior to target quit date reduces prequit date smoking and increases 12-week abstinence]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100147v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Efficacy of varenicline for tobacco cessation has been attributed to its partial agonist activity at selective nicotinic acetylcholine receptors.<cross-ref type="bib" refid="R1">1</cross-ref> This mechanism of action is thought to reduce withdrawal symptoms, while competitively occupying receptors linked to reward pathways to decrease smoking enjoyment and intake.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> When combined with counselling, varenicline can improve smoking abstinence rates two to threefold.<cross-ref type="bib" refid="R3">3</cross-ref> <cross-ref type="bib" refid="R4">4</cross-ref></p><p>Most clinical trials of varenicline initiated therapy 1 week prior to target quit date (TQD).<cross-ref type="bib" refid="R3">3</cross-ref> <cross-ref type="bib" refid="R4">4</cross-ref> <cross-ref type="bib" refid="R5">5</cross-ref> In a &lsquo;proof-of-principle&rsquo; study, Hajek <I>et al</I> compared varenicline 1 week versus 4 weeks (extended preloading) prior to TQD. Efficacy measures included continuous abstinence rates (CAR) at 4 weeks and 12 weeks after TQD; cigarette intake and smoking enjoyment before quitting; and urges to smoke and withdrawal symptoms after quitting.</p></sec><sec id="s2"><st>Methods</st><p>A total of 101 adult volunteers enrolled at a...]]></description>
<dc:creator><![CDATA[Garrison, G. D.]]></dc:creator>
<dc:date>2011-12-07T22:08:37-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100147</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100147</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Smoking and tobacco, Clinical trials (epidemiology), Drugs: CNS (not psychiatric), Drugs misuse (including addiction), Tobacco related disease, Health education, Smoking]]></dc:subject>
<dc:title><![CDATA[Varenicline for 4 weeks prior to target quit date reduces prequit date smoking and increases 12-week abstinence]]></dc:title>
<prism:publicationDate>2011-12-07</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100230v1?rss=1">
<title><![CDATA[Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials?]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100230v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>The majority of patients with diabetes continue to die from cardiovascular causes. The degree to which improved glucose control could help to address this risk has been examined in recent large trials<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3">3</cross-ref> comparing intensive with usual blood glucose-lowering strategies. This meta-analysis pools the findings from these recent trials as well as several older trials with the aim of defining the effects of intensive control on mortality, cardiovascular events and microvascular events in patients with type 2 diabetes.</p></sec><sec id="s2"><st>Methods</st><p>Boussageon <I>et al</I> conducted a pooled analysis using published data from 13 trials selected on the basis of having an intensive glucose-lowering treatment arm compared with either a &lsquo;standard&rsquo; treatment, less intensive glycaemic lowering or placebo. The authors used a comprehensive search strategy and extraction methods to identify relevant published data. The authors also calculated absolute risk reductions and assessed the impacts of trial quality.</p></sec><sec id="s3"><st>Findings</st><p>The...]]></description>
<dc:creator><![CDATA[Turnbull, F., Zoungas, S.]]></dc:creator>
<dc:date>2011-11-28T22:36:06-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100230</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100230</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Ophthalmology, Ischaemic heart disease, Diabetes]]></dc:subject>
<dc:title><![CDATA[Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials?]]></dc:title>
<prism:publicationDate>2011-11-28</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100278v1?rss=1">
<title><![CDATA[Antiretroviral combination therapy markedly reduces risk of heterosexual HIV-1 transmission]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100278v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>The reduction of HIV-1 transmission remains one of the highest global health priorities. The use of established antiretroviral drugs for preventing HIV-1 transmission was first considered in 1994, after an observational clinical study showed reduced HIV-1 infection rates in partners of HIV-1 infected persons treated with zidovudine monotherapy.<cross-ref type="bib" refid="R1">1</cross-ref> In 2007, the HIV Prevention Trials Network (HPTN) initiated a randomised-controlled clinical trial (HPTN 052) in which the effect of antiretroviral combination therapy on heterosexual transmission of HIV-1 was evaluated; the results have recently been reported.</p></sec><sec id="s2"><st>Methods</st><p>HPTN 052 is a phase III, randomised-controlled clinical trial designed to determine if early initiation of antiretroviral therapy could reduce transmission of HIV-1 in serodiscordant partners, compared with delayed treatment (after a decline in CD4 counts or the onset of HIV symptoms). The principal outcome measures were (i) the rates of new HIV-1 infections in partners of infected subjects, (ii) the frequency of...]]></description>
<dc:creator><![CDATA[Lichterfeld, M., Rosenberg, E. S.]]></dc:creator>
<dc:date>2011-11-22T00:08:32-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100278</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100278</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Sexual transmitted infections (viral), Immunology (including allergy), HIV/AIDS]]></dc:subject>
<dc:title><![CDATA[Antiretroviral combination therapy markedly reduces risk of heterosexual HIV-1 transmission]]></dc:title>
<prism:publicationDate>2011-11-22</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100206v1?rss=1">
<title><![CDATA[Tiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting {beta}(2)-agonist remains unclear]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100206v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Clinical practice guidelines (CPG) for the management of stable chronic obstructive pulmonary disease (COPD) recommend the addition of long-acting bronchodilators for patients who remain symptomatic despite use of short-acting bronchodilators.<cross-ref type="bib" refid="R1">1</cross-ref> Whether a long-acting muscarinic antagonist (anticholinergic) bronchodilator (LAMA) such as tiotropium or a long-acting &beta;<SUB>2</SUB>-agonist bronchodilator (LABA) such as salmeterol, formoterol or indacaterol should be used as initial therapy is a matter of debate.</p><p>If symptoms persist despite the use of tiotropium, CPGs recommend adding a LABA. In practice, the LABA added usually includes inhaled corticosteroid (ICS) as a combination inhaler (LABA/ICS: salmeterol/fluticasone or formoterol/budesonide). Occasionally, a LABA/ICS is used instead of tiotropium as initial therapy, although this is not recommended by evidence-based CPGs. Finally, although commonly used for moderate-to-severe COPD, there has been little research into the effectiveness of so-called &lsquo;triple therapy&rsquo;, namely a LABA/ICS plus LAMA. This commentary examines two recent studies that have attempted to...]]></description>
<dc:creator><![CDATA[Hodder, R.]]></dc:creator>
<dc:date>2011-11-22T00:08:32-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100206</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100206</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Drugs: CNS (not psychiatric), Drugs: respiratory system, Guidelines]]></dc:subject>
<dc:title><![CDATA[Tiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting {beta}(2)-agonist remains unclear]]></dc:title>
<prism:publicationDate>2011-11-22</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed.2011.100310v1?rss=1">
<title><![CDATA[Observational studies find association between chocolate consumption and reduced risk of cardiovascular disease and diabetes]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed.2011.100310v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Cardiovascular disease is the leading cause of death in industrialised nations and is associated with high costs. Hence, identifying cost-effective measures to prevent such a disease and its risk factors that are palatable remains a top priority for public health. Modifiable lifestyle factors including dietary habits have been recognised as a cornerstone in the prevention of cardiovascular disease. Among healthy food groups, beneficial effects of whole grains, fruits and vegetables, nuts and low sodium intake on heart disease have been well documented, perhaps, partially due to a high content of flavonoids of those foods. Cocoa and dark chocolate are a natural source of flavonoids and consumption of dark chocolate may confer cardiovascular benefits. However, there are limited and inconsistent data on the effects of chocolate consumption on cardiovascular disease.</p></sec><sec id="s2"><st>Methods</st><p>Buitrago-Lopez <I>et al</I> completed a systematic review and meta-analysis to synthesise current evidence on the association between chocolate consumption and...]]></description>
<dc:creator><![CDATA[Djousse, L.]]></dc:creator>
<dc:date>2011-11-15T03:27:15-08:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed.2011.100310</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed.2011.100310</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Immunology (including allergy), Drugs: cardiovascular system, Stroke, Diet, Obesity (nutrition), Health education]]></dc:subject>
<dc:title><![CDATA[Observational studies find association between chocolate consumption and reduced risk of cardiovascular disease and diabetes]]></dc:title>
<prism:publicationDate>2011-11-15</prism:publicationDate>
<prism:section>Aetiology</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100167v1?rss=1">
<title><![CDATA[Stopping smoking in the weeks prior to surgery has no effect on the risk of postoperative complications]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100167v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Prior studies show mixed results regarding the harms and benefits of smoking cessation prior to surgery. In one study, cigarette smoking demonstrated an increased risk of peri- and postoperative complications compared with not smoking.<cross-ref type="bib" refid="R1">1</cross-ref> A recent systematic review found that smoking cessation interventions 4&ndash;8 weeks before surgery not only promote tobacco abstinence but reduce postoperative surgical complications.<cross-ref type="bib" refid="R2">2</cross-ref> Whether to advise a smoker to stop smoking in the immediate preoperative period is controversial because sparse data suggest that smoking cessation might increase postoperative pulmonary complications due to a temporary increase in sputum production and a decreased cough reflex.<cross-ref type="bib" refid="R3">3</cross-ref> This systematic review examines whether quitting smoking within 8 weeks before surgery is associated with postoperative complications.</p></sec><sec id="s2"><st>Methods</st><p>A systematic review with meta-analysis included studies through May 2010 that assessed postoperative complications in patients who had quit smoking 8 weeks or less before surgery, and included a...]]></description>
<dc:creator><![CDATA[Clair, C., Rigotti, N. A.]]></dc:creator>
<dc:date>2011-11-04T07:23:37-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100167</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100167</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Smoking and tobacco, Epidemiologic studies, Health education, Smoking]]></dc:subject>
<dc:title><![CDATA[Stopping smoking in the weeks prior to surgery has no effect on the risk of postoperative complications]]></dc:title>
<prism:publicationDate>2011-11-04</prism:publicationDate>
<prism:section>Prognosis</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebmed-2011-100215v1?rss=1">
<title><![CDATA[Meta-analysis: vertebroplasty for vertebral compression fracture ineffective in improving pain and function]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebmed-2011-100215v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Osteoporotic vertebral compression fractures (VCF) are a significant public health concern worldwide. Percutaneous vertebral augmentation or vertebroplasty was introduced to alleviate the pain and reduce the disability associated with VCF in patients failing conservative therapy, but were at very high-risk for open surgery. Due to the apparent success and low morbidity of vertebroplasty, these indications were expanded and widespread use ensued until several randomised trials evaluated the efficacy of vertebroplasty in VCF.<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3"></cross-ref><cross-ref type="bib" refid="R4"></cross-ref><cross-ref type="bib" refid="R5">5</cross-ref> Of these, two double-blind sham-controlled randomised trials (ie, the INVEST and Australian trials) demonstrated that vertebroplasty is no more effective than sham surgery.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> This finding contradicts the existing prolific observational literature, and caused significant debate among the experts in this field.<cross-ref type="bib" refid="R6">6</cross-ref> <cross-ref type="bib" refid="R7">7</cross-ref> The main criticisms of this Level I evidence are the trials that show selection bias, include...]]></description>
<dc:creator><![CDATA[Frankel, B. M., Krishna, V.]]></dc:creator>
<dc:date>2011-11-01T00:30:39-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebmed-2011-100215</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebmed-2011-100215</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Epidemiologic studies, Pain (neurology), Pain (palliative care), Radiology, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Osteoporosis, Clinical diagnostic tests, Ethics, Injury]]></dc:subject>
<dc:title><![CDATA[Meta-analysis: vertebroplasty for vertebral compression fracture ineffective in improving pain and function]]></dc:title>
<prism:publicationDate>2011-11-01</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100183v1?rss=1">
<title><![CDATA[Oxytocin for slow progress in the first stage of spontaneous labour is not associated with different rates of caesarean or assisted delivery compared with no treatment or delayed use in second stage]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100183v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Bugg <I>et al</I> discuss the important question of whether labour augmentation with oxytocin would decrease the duration of labour. This treatment is part of active management of labour, a concept that also includes objective diagnosis of labour and early amniotomy.<cross-ref type="bib" refid="R1">1</cross-ref> Slow progress of labour or ineffective uterine activity has been quoted as the cause of caesarean sections in 35% of women with cephalic pregnancies<cross-ref type="bib" refid="R2">2</cross-ref> and as a possible cause for an increase in maternal and foetal morbidity.<cross-ref type="bib" refid="R3">3</cross-ref> <cross-ref type="bib" refid="R4">4</cross-ref> Several types of abnormal labour can be studied.</p><p>In 1989, the American College of Obstetricians and Gynaecologists suggested that arrest of the first stage of labour cannot be diagnosed until both the latent phases have been completed with the cervix dilated 4 cm or more and a uterine contraction pattern has been present for 2 h without cervical change.<cross-ref type="bib" refid="R5">5</cross-ref> More recent studies...]]></description>
<dc:creator><![CDATA[Frolich, M.]]></dc:creator>
<dc:date>2011-10-28T05:01:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100183</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100183</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Drugs: CNS (not psychiatric), Pain (neurology), Contraception, Drugs: obstetrics and gynaecology, Pregnancy, Pain (palliative care), Pain (anaesthesia)]]></dc:subject>
<dc:title><![CDATA[Oxytocin for slow progress in the first stage of spontaneous labour is not associated with different rates of caesarean or assisted delivery compared with no treatment or delayed use in second stage]]></dc:title>
<prism:publicationDate>2011-10-28</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100193v1?rss=1">
<title><![CDATA[In people with newly diagnosed type 2 diabetes an intensive dietary intervention, with or without an activity programme, improves glycaemic control over 12 months compared with usual care]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100193v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Lifestyle modification is the cornerstone of treatment in type 2 diabetes. Improved nutrition or increased physical activity both improve glycaemic control,<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> but whether diet and exercise have a synergistic effect is not established. This study examined whether an intensive dietary intervention plus physical activity advice had additional benefits compared with an intensive dietary intervention only in newly diagnosed type 2 diabetes patients.</p></sec><sec id="s2"><st>Methods</st><p>This 52-week multicentre trial in South West England involved 593 patients aged 31 to 80 years with type 2 diabetes diagnosed 5&ndash;8 months previously randomised with concealed allocation to three groups: usual care (control group), intensive diet and intensive diet plus physical activity, in a 2:5:5 ratio. Exclusion criteria included HbA1c &gt;10%, blood pressure &gt;180/100 mm Hg, <I>low-density lipoprotein</I> cholesterol &gt;4 mmol/l, body mass index lower than 25 kg/m<sup>2</sup> and weight &gt;180 kg. Potential participants were initially screened by phone and 712...]]></description>
<dc:creator><![CDATA[Coppell, K.]]></dc:creator>
<dc:date>2011-10-28T05:01:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100193</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100193</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Hypertension, Diet, Diabetes, Health education]]></dc:subject>
<dc:title><![CDATA[In people with newly diagnosed type 2 diabetes an intensive dietary intervention, with or without an activity programme, improves glycaemic control over 12 months compared with usual care]]></dc:title>
<prism:publicationDate>2011-10-28</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100212v1?rss=1">
<title><![CDATA[High-quality evidence that spinal manipulative therapy for chronic low back pain has a small, short-term greater effect on pain and functional status compared with other interventions]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100212v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Chronic low back pain continues to be a major socioeconomic problem in most parts of the world. Spinal manipulative therapy is one of the several conservative treatment options, which, based on results from numerous randomised clinical trials, has been included as one of the recommended therapies in several national clinical guidelines.</p></sec><sec id="s2"><st>Methods</st><p>Rubinstein <I>et al</I> systematically evaluated evidence from randomised, placebo or active comparative clinical trials in which spinal manipulative therapy (spinal manipulation and/or spinal mobilisation) was used to treat chronic low back pain in adults. This represents an update from an earlier Cochrane review and the authors identified the latest trials by searching Cochrane CENTRAL, MEDLINE, EMBASE, CINAHL, PEDro and the Index to Chiropractic Literature. The primary outcomes were pain, functional status and perceived recovery. Secondary outcomes were return-to-work and quality of life. Studies with patients of &gt;18 years of age from primary, secondary or tertiary care with non-specific...]]></description>
<dc:creator><![CDATA[Bronfort, G.]]></dc:creator>
<dc:date>2011-10-25T09:52:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100212</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100212</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Rehabilitation medicine, Health policy, Neuromuscular disease, Pain (neurology), Peripheral nerve disease, Pain (palliative care), Sports and exercise medicine, Health economics, Health service research, Guidelines]]></dc:subject>
<dc:title><![CDATA[High-quality evidence that spinal manipulative therapy for chronic low back pain has a small, short-term greater effect on pain and functional status compared with other interventions]]></dc:title>
<prism:publicationDate>2011-10-25</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100221v1?rss=1">
<title><![CDATA[Inhaled corticosteroids for people with chronic obstructive pulmonary disease are associated with an increased risk of fracture]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100221v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Inhaled corticosteroids (ICS) are recommended for the management of moderate to severe chronic obstructive pulmonary disease (COPD).<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> Previous investigations on the adverse effects of ICS on bone health in individuals with COPD have yielded conflicting results. Some trials<cross-ref type="bib" refid="R3">3</cross-ref> have found that ICS can worsen bone mineral density (BMD) but not fracture risk, whereas other studies<cross-ref type="bib" refid="R4">4</cross-ref> <cross-ref type="bib" refid="R5">5</cross-ref> have found no such effect. Meta-analyses have also yielded contradictory findings.<cross-ref type="bib" refid="R6">6</cross-ref> <cross-ref type="bib" refid="R7">7</cross-ref> Understanding the strength and characteristics of this association is important as fractures can have serious consequences in patients with COPD.</p></sec><sec id="s2"><st>Methods</st><p>This study evaluated randomised clinical trials (RCTs) of ICS (budesonide or fluticasone) or ICS with a long-acting &beta; agonist (LABA) versus placebo or LABA alone over a follow-up period of at least 24 weeks. The authors also assessed the outcomes of observational studies with respect to...]]></description>
<dc:creator><![CDATA[Putcha, N., Drummond, M. B.]]></dc:creator>
<dc:date>2011-10-25T09:52:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100221</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100221</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Journalology, Clinical trials (epidemiology), Drugs: respiratory system]]></dc:subject>
<dc:title><![CDATA[Inhaled corticosteroids for people with chronic obstructive pulmonary disease are associated with an increased risk of fracture]]></dc:title>
<prism:publicationDate>2011-10-25</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100162v1?rss=1">
<title><![CDATA[Averaging clinic and home measures associated with reductions in within-patient variability and may give a better indication of blood pressure control]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100162v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>In 2003,<cross-ref type="bib" refid="R1">1</cross-ref> European guidelines addressed the variability in blood pressure (BP) measurements. They proposed that two or more readings at 1-min intervals be taken at each visit,<cross-ref type="bib" refid="R1">1</cross-ref> with further readings in case of uncertainty. They also stated that the alarm reaction to BP measurement may persist after several visits, so for patients with sustained elevation of BP, more measurements should be obtained on different occasions over a number of weeks or months before diagnostic or management decisions are made. Alternatively, ambulatory BP measurement or self-measurement of BP away from the medical environment should be performed.<cross-ref type="bib" refid="R1">1</cross-ref> In a secondary analysis of the Hypertension Intervention Nurse Telemedicine Study (HINTS),<cross-ref type="bib" refid="R2">2</cross-ref> Powers <I>et al</I> attempted to determine the optimal setting and number of BP measurements that should be used for clinical decision making.</p></sec><sec id="s2"><st>Methods</st><p>The HINTS<cross-ref type="bib" refid="R2">2</cross-ref> was a randomised trial that enrolled patients with...]]></description>
<dc:creator><![CDATA[Asayama, K., Thijs, L., Staessen, J. A.]]></dc:creator>
<dc:date>2011-10-25T09:52:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100162</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100162</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Health informatics, Hypertension]]></dc:subject>
<dc:title><![CDATA[Averaging clinic and home measures associated with reductions in within-patient variability and may give a better indication of blood pressure control]]></dc:title>
<prism:publicationDate>2011-10-25</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100238v1?rss=1">
<title><![CDATA[Review: excisional, and perhaps ablative treatments for precancerous cervical changes increase the risk for preterm birth]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100238v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Cervical intraepithelial neoplasia (CIN) is a common complication in women of reproductive age. Treatment options include excisional treatments, such as cold knife conisation, loop electrosurgical excision procedure, large loop excision of the transformation zone (LLETZ) and laser conisation; and ablative treatments, including cryotherapy, laser ablation, cold coagulation and diathermy. These treatments may have an impact on subsequent pregnancy outcomes. The meta-analysis by Bruinsma and Quinn evaluates the effect of the type of comparison group on the association between treatment for CIN and subsequent preterm birth &lt;37 weeks gestation.</p></sec><sec id="s2"><st>Methods</st><p>The authors performed a meta-analysis of cohort studies published between 1950 and 2009, evaluating subsequent pregnancy outcome of women who had singleton gestations and who had undergone treatment for CIN. They included both ablative and excisional treatments, but evaluated the treatments separately. Comparisons were of three types: (1) external comparison group of women who gave birth during the same time period...]]></description>
<dc:creator><![CDATA[Crane, J.]]></dc:creator>
<dc:date>2011-10-25T09:52:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100238</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100238</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Rehabilitation medicine, Epidemiologic studies, Pregnancy, Radiology, Vulvovaginal disorders, Sports and exercise medicine, Surgical diagnostic tests, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Review: excisional, and perhaps ablative treatments for precancerous cervical changes increase the risk for preterm birth]]></dc:title>
<prism:publicationDate>2011-10-25</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100202v1?rss=1">
<title><![CDATA[Uterine artery embolisation associated with greater need for reintervention than surgical treatment for symptomatic uterine fibroids; quality of life similar though study underpowered]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100202v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Symptomatic uterine fibroids may be managed surgically, with hysterectomy or myomectomy, or by radiological therapies, including uterine artery embolisation (UAE) or high-intensity focused ultrasound. The specialty societies in the USA (<A HREF="http://www.acog.org">www.acog.org</inter-ref>) and the UK (<inter-ref locator="http://www.rcog.org.uk" locator-type="url">www.rcog.org.uk</A>) and the National Institute for Clinical Excellence have endorsed the safety and short-term efficacy of UAE, but have identified research needs to study long-term symptom relief and fertility effects. Effective non-surgical options for fibroids are needed, particularly to preserve fertility. Short-term follow-up suggests that UAE reduces symptoms and may be more cost effective than surgery.1 Longer follow-up now questions the durability of these outcomes.</p></sec><sec id="s2"><st>Methods</st><p>This paper reports the 5-year follow-up data from a pragmatic, unblinded randomised controlled trial in 27 centres in the UK, studying women who had &ge;1 symptomatic fibroids, complained of menorrhagia or bulk symptoms, and were candidates for surgery (n=157). Randomisation (done centrally and held by a...]]></description>
<dc:creator><![CDATA[Hickey, M., Marino, J. L., Brownfoot, F. C.]]></dc:creator>
<dc:date>2011-10-25T09:52:07-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100202</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100202</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Pain (neurology), Radiology, Clinical diagnostic tests, Radiology (diagnostics)]]></dc:subject>
<dc:title><![CDATA[Uterine artery embolisation associated with greater need for reintervention than surgical treatment for symptomatic uterine fibroids; quality of life similar though study underpowered]]></dc:title>
<prism:publicationDate>2011-10-25</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100252v1?rss=1">
<title><![CDATA[Early supplemental parenteral nutrition in critically ill adults increased infections, ICU length of stay and cost]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100252v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Historically, there has been considerable controversy regarding the timing of supplemental parenteral nutrition (PN) in the critical care setting. Guideline recommendations range from continued underfeeding with enteral nutrition (EN) alone for up to 7&ndash;10 days<cross-ref type="bib" refid="R1">1</cross-ref> to the addition of supplemental PN within 24&ndash;48 h in patients who are expected to be intolerant to EN within 72 h of admission.<cross-ref type="bib" refid="R2">2</cross-ref> Proponents of early supplemental PN have focused on data demonstrating that the cumulative energy deficit or caloric debt is associated with adverse clinical outcomes while opponents cite the literature demonstrating increased adverse events in patients who receive PN during their intensive care unit (ICU) stay. The recent publication by Casaer <I>et al</I> addresses this controversy.</p></sec><sec id="s2"><st>Methods</st><p>In this large-scale, unblinded, multicentre trial, Casaer <I>et al</I> randomised 4640 seriously ill ICU patients who were not taking oral nutrition to receive early PN or late PN. Both groups received...]]></description>
<dc:creator><![CDATA[Heyland, D. K.]]></dc:creator>
<dc:date>2011-10-25T09:52:06-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100252</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100252</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Health policy, Epidemiologic studies, Health economics, Health service research]]></dc:subject>
<dc:title><![CDATA[Early supplemental parenteral nutrition in critically ill adults increased infections, ICU length of stay and cost]]></dc:title>
<prism:publicationDate>2011-10-25</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100231v1?rss=1">
<title><![CDATA[In premenopausal women with recurrent UTI, antibiotics were more effective than capsules of cranberry extract for the prevention of UTI, but resistance was higher in the antibiotic group]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100231v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Clinical recurrence (CR) of urinary tract infection (UTI) is common in premenopausal women. Practice guidelines recommend 6&ndash;12 months of prophylactic antibiotics for CR of UTI. A meta-analysis demonstrated that prophylaxis with antibiotics was 85% (RR 0.15, (0.08 to 0.28)) better than placebo in pre and postmenopausal women. However, antibiotics cause adverse effects (AEs) (RR 1.58 (0.47 to 5.28)) and antimicrobial resistance<cross-ref type="bib" refid="R1">1</cross-ref> prompting great interest in safer prophylaxis options. In a meta-analysis of two randomised control trials, cranberries were 39% (RR 0.61, (0.40 to 0.91)) better than placebo in preventing CR of UTI in premenopausal women without causing severe AEs.<cross-ref type="bib" refid="R2">2</cross-ref> In postmenopausal women, antibiotics were similar to cranberries in reducing CR of UTI.<cross-ref type="bib" refid="R3">3</cross-ref> Beerepoot <I>et al</I> aimed to demonstrate that cranberries are non-inferior to antibiotics in preventing CR of UTI in premenopausal women.</p></sec><sec id="s2"><st>Methods</st><p>In this non-inferiority double blind randomised trial, subjects were community dwelling...]]></description>
<dc:creator><![CDATA[Genao, L.]]></dc:creator>
<dc:date>2011-10-20T05:43:39-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100231</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100231</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Immunology (including allergy), Urinary tract infections, Menopause (including HRT), Pregnancy, Interventional cardiology, Vulvovaginal disorders, Urinary tract infections]]></dc:subject>
<dc:title><![CDATA[In premenopausal women with recurrent UTI, antibiotics were more effective than capsules of cranberry extract for the prevention of UTI, but resistance was higher in the antibiotic group]]></dc:title>
<prism:publicationDate>2011-10-20</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
<item rdf:about="http://ebm.bmj.com/cgi/content/short/ebm.2011.100121v1?rss=1">
<title><![CDATA[Metformin is not significantly different from insulin for preventing fetal macrosomia in women with gestational diabetes]]></title>
<link>http://ebm.bmj.com/cgi/content/short/ebm.2011.100121v1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Context</st><p>Evidence is accumulating that metformin is a safe alternative to insulin for the treatment of gestational diabetes mellitus (GDM) not adequately controlled by dietary measures alone.<cross-ref type="bib" refid="R1">1</cross-ref> <cross-ref type="bib" refid="R2">2</cross-ref> The UK National Institute for Health and Clinical Excellence (NICE) guidance for diabetes in pregnancy now includes metformin as a treatment option.<cross-ref type="bib" refid="R3">3</cross-ref> However metformin is still not widely accepted for the management of GDM and remains unlicensed for this indication in the UK. The study by Ijas and colleagues adds to the evidence base for its use in GDM.</p></sec><sec id="s2"><st>Method</st><p>In an open-label prospective study, the Finnish team randomised 100 women (out of a total of 128 eligible women) with singleton pregnancies diagnosed with GDM by oral glucose tolerance test (fasting capillary glucose 5.3 (baseline), 11.0 (1 h) and 9.6 (2 h) mmol/l after 75 g oral glucose) between 12 and 34 weeks of gestation to either...]]></description>
<dc:creator><![CDATA[Hyer, S. L.]]></dc:creator>
<dc:date>2011-09-21T00:16:11-07:00</dc:date>
<dc:identifier>info:doi/10.1136/ebm.2011.100121</dc:identifier>
<dc:identifier>hwp:master-id:ebmed;ebm.2011.100121</dc:identifier>
<dc:publisher>Royal Society of Medicine</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Genetics, Childhood nutrition, Diet, Pregnancy, Diabetes, Injury]]></dc:subject>
<dc:title><![CDATA[Metformin is not significantly different from insulin for preventing fetal macrosomia in women with gestational diabetes]]></dc:title>
<prism:publicationDate>2011-09-21</prism:publicationDate>
<prism:section>Therapeutics</prism:section>
</item>
</rdf:RDF>
